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1. ABSTRACT 
 
 
Tristetraprolin (TTP) is a prototypic family member of the cystein-cystein-cystein-histidin (CCCH)-type 
tandem zinc-finger (TZF) domain proteins that regulate mRNA stability in eukaryotic cells. TTP specifically 
binds to AU-rich elements (AREs) in the 3’-untranslated region (UTR) of certain mRNAs exhibiting high 
turnover rates (e.g. cytokines, growth factors or proto-oncogenes), recruits components of the RNA-decay 
machinery via its N- and C-terminal domains and thereby facilitates the rapid degradation of the 
transcripts. Described targets that undergo this so called ARE-mediated decay (AMD) include tumor 
necrosis factor α (TNFα), granulocyte macrophage colony-stimulating factor (GM-CSF) and immediate 
early response 3 (Ier3).  
TTP is an inducible, hyperphosphorylated protein. Phosphorylation by the mitogen-activated-protein-
kinase (MAPK) p38-MK2 leads to its stabilization and accumulation in the cell, but at the same time to the 
inactivation of its mRNA degrading function. In endothelial cells, expression of TTP is up-regulated by a 
variety of agents including inflammatory mediators such as TNFα.  TNF receptor (TNFR) engagement 
leads to the concomitant activation of MAPKs and IKKs (inhibitor of κB kinase) resulting in the onset of 
p38, JNK (c-Jun N-terminal kinase) and nuclear factor kappa B (NF-κB) signaling cascades. These trigger 
biological responses reaching from proliferation and differentiation to inflammatory responses and 
apoptosis.  
We describe here a novel, AMD-independent function of TTP in regard to the transcription factor NF-
κB: TTP suppresses the transcriptional activity of NF-κB dependent promoters independent of its mRNA 
destabilizing property. This is evidenced by several gain- and loss-of-function experiments, e.g. in TTP 
knock out (k.o) mouse embryonic fibroblasts (MEF), lack of TTP leads to enhanced nuclear p65 levels and 
activity, which are associated with the upregulation of certain ARE-less NF-κB target genes. The 
attenuation of NF-κB activity is at least in part due to an interference of TTP with the nuclear import of 
the p65 subunit of the transcription factor.  
In addition the presented data suggest that the MAP3K MEKK1 phosphorylates TTP leading to its K63-
linked polyubiquitination, which impacts cell viability in HEK 293 cells. This is associated with strongly 
impaired JNK activity in TTP k.o MEF. In human umbilical vein endothelial cells (HUVEC) TTP was found to 
be involved in the onset of apoptosis in a TNFα independent and dependent manner.  
This novel inhibitory function of TTP towards NF-κB may synergize with its mRNA degrading ability to 
contribute to the coordinated crosstalk between NF-κB and MAPK cascades, facilitating a flexible response 
to incoming signals and cellular requirements. 
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1. ZUSAMMENFASSUNG 
 
 
Tristetraprolin (TTP) ist ein klassischer Vertreter einer Proteinfamilie, die als typisches Merkmal 
sogenannte Tandem-Zinkfinger-Strukturen aufweisen. Diese Motive bestehen jeweils aus drei Cysteinen 
und einem Histidin (CCCH) und sind maßgeblich an der mRNA Degradierung in eukaryotischen Zellen 
beteiligt. TTP bindet spezifisch an sogenannte AU-reiche Elemente (ARE), die sich hauptsächlich in der 3’-
untranslatierten Region von mRNAs befinden, welche eine hohe Turnover-Rate aufweisen, wie zum 
Beispiel Cytokine, Wachstumsfaktoren oder auch Proto-Onkogene.  In der Folge rekrutiert TTP mit Hilfe 
seiner N- und C-terminalen Proteindomänen Faktoren der RNA-Degradierungsmaschinerie und führt so 
zum schnellen Abbau der Transkripte. Typische mRNAs, die über diesen sogenannten ARE-gesteuerten 
Abbau (AMD) degradiert werden, sind unter anderem TNFα, GM-CSF und Ier3.   
TTP ist ein durch verschiedene Faktoren induzierbares, hyperphosphoryliertes Protein, wobei die 
Phosphorylierung durch die Mitogen-aktivierte-Proteinkinase (MAPK) p38-MK2 einerseits zur Stabilisierung 
und Akkumulation von TTP, und andererseits zur Inaktivierung der mRNA-Degradierungsfunktion führt. In 
Endothelzellen wird die Expression von TTP durch verschiedenste Stimuli hochreguliert, zum Beispiel 
durch das proinflammatorische Protein TNFα, welches ein typisches Mitglied der TNF-Familie darstellt. Die 
Bindung eines Liganden an einen entsprechenden Rezeptor der TNFR Familie führt immer zur 
gleichzeitigen Aktivierung von MAPKs und IKKs (Inhibitor der κB Kinase), welche folglich p38, JNK und 
NF-κB Signalkaskaden aktivieren. Dies führt zur Expression von Genen, die verschiedenste biologische 
Prozesse wie Proliferation, Zelldifferenzierung, inflammatorische Antworten aber auch Apoptose,  
kontrollieren. 
Wir beschreiben hier eine neue, AMD-unabhängige Funktion von TTP: es inhibiert NF-κB-abhängige 
Promotoren unabhängig von seiner Funktion mRNAs zu degradieren. TTP knock out MEFs zum Beispiel 
zeigen erhöhte, nukleäre p65-Levels, die weiters mit der Hochregulation von spezifischen, ARE-losen NF-
κB-target Genen einhergehen. Im Rahmen dieser Arbeit wird auch gezeigt, dass der zugrunde liegende 
Mechanismus, zumindest zum Teil, eine Blockade des nukleären Imports der NF-κB-Untereinheit p65 
durch TTP ist. Weiters konnte gezeigt werden, dass die Phosphorylierung von TTP, hervorgerufen durch 
die MAP3K MEKK1, zur K63-verknüpften Ubiquitinylierung des Proteins führt und die Viabilität von HEK 
293 Zellen stark beeinflusst. Dies unterstützt die Tatsache, dass TTP knock out MEF eine auffallend 
schwache JNK Aktivierung zeigen, sowie dass TTP an der TNFα unabhängigen, und auch abhängigen 
Apoptose in HUVEC beteiligt ist. Diese neue regulatorische Rolle von TTP könnte in Kombination mit der 
bereits beschriebenen mRNA-Destabilisierungsfunktion zur verbesserten Koordination von NF-κB und 
MAPK Signaltransduktion beitragen und dadurch die Grundlage für eine angemessene und umfassende 
Antwort einer Zelle auf vielerlei unterschiedliche Signale und Bedingungen bilden. 
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2. INTRODUCTION 
 
 
 
2.1. Inflammation 
 
Inflammation is defined as a complex biological process that constitutes a protective mechanism to 
defend an organism against injurious triggers, prevents tissue destruction, initiates healing and is 
therefore the main actor in maintaining tissue homeostasis. Inflammation is classified in acute and chronic 
response and whereas the former brings benefit to the organism the latter causes detrimental effects 
which are reflected by a variety of diseases including e.g. atherosclerosis.  
Acute inflammation is known as the initial, immediate response to injury and is characterized by the 
increased movement of leukocytes and plasma from the blood into the harmed tissue, resulting in the 
onset of repair mechanisms. These facilitate the removal of damaged cells, killing of invaders and finally 
promote cell replacement. In principle, acute inflammation is divided into three main phases, namely the 
inductive or initiation phase, which is followed by a sustained response that finally becomes terminated 
when triggers of the initial response are resolved [1, 2].  At the onset of inflammation cells of the innate 
immune system, mainly resident macrophages and dendritic cells, undergo activation leading to the 
release of so-called inflammatory mediators which are indispensable for the appropriate progression of 
the response.  
 
 
2.1.1. Activation of the inflammatory response 
 
Classical signs of inflammatory activation are increased blood flow causing extensive redness and 
increased heat, as well as enhanced permeability of blood vessels leading to the leakage of plasma 
proteins into the tissue and resulting in swelling. One of the most important steps in the initiation and 
maintenance of inflammation is the migration of leukocytes from the blood stream through the vessel wall 
to the site of injured tissue. Coordinated migration of mainly neutrophils is thereby achieved by a 
chemotactic gradient [3] and can be devided into different steps: recruitment and adhesion to the 
endothelium, transmigration via diapedesis and finally movement within the tissue via chemotaxis. 
Recruitment of leukocytes is mainly a receptor mediated process whereby proinflammatory mediators 
such as histamines, TNFα, Interleukin-1 (IL-1) or Lipopolysaccharide (LPS) trigger the expression of 
different receptors, including P- and E-selectin, on the endothelial cell surface. These are quite weakly 
bound by ligands on the surface of leukocytes (e.g. L-selectin, PSGL-1 or α4-integrins) which forces them 
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to slow down and “roll” along the endothelial surface by means of alternating bonding and release [4]. 
Further activation of leukocytes through the release of chemokines finally attaches them to the 
endothelium (Fig. 1T). Once adhered, chemokine gradients induce leukocyte movement through the 
basement membrane into the tissue and further assure the directed movement towards the source of 
inflammation.  Based  on  the  above described  process  it  gets  obvious  that  the  endothelium plays an  
 
  
 
Fig. 1T: Leukocyte-adhesion is a multistep cascade. Leukocytes undergo four adhesion steps to accumulate at a specific site within the blood 
vessel: tethering, rolling, activation and arrest (top). Thereby they express trafficking mediators specific for each step which act as ligands for their 
endothelial counter-receptors (bottom). Leukocyte-receptors such as L-selectin, PSGL-1 and α4-integrins mediate tethering and rolling and interact with 
ligands on inflamed endothelial cells as E-selectin, P-selectin and peripheral node addressin (PNAd). Thereby L- and P-selectin mediate rolling whereas 
E-selctin and α4-integrins act as rolling-stabilizers. Of equal importance are the G-protein-coupled receptors (GPCR) on rolling cells. These receptors 
become engaged by e.g. chemokines which finally leads to an intracellular signal transmission and the rapid activation of β2 and α4-integrins. This 
results in a tight fixation to the endothelial surface by interaction with molecules of the endothelial immunoglobulin superfamily as ICAMs, VCAMs or 
MAdCAM. Interactions of molecules with their binding partner(s) are visualized by arrows. (PAF, platelet-activating factor; LTB4, 5-lipoxygenase 
pathway producto leukotriene B4; Mac-1, myeloid cell-associated marker). 
 
 
important role in the regulation and control of inflammatory processes. As a normally nonadhesive barrier 
between blood stream and tissues, basically impermeable to macromolecules, it undergoes diverse 
changes in permeability and adhesiveness, processes regulated by a complex interplay between incoming 
inflammatory signals, release of mediators that lead to the engagement of receptors, and the final 
activation of a variety of cellular responses. Main proinflammatory mediators include cytokines such as IL-
1 or TNFα, which promote the progression of the response and trigger the coordinated interplay of 
different signaling cascades. One of the activated key regulators in cytokine-initiated proinflammatory 
signaling is the dimeric transcription factor NF-κB that accounts for a highly selective regulation of 
different sets of genes. These include proinflammatory cytokines, adhesion molecules (E-selectin, vascular 
adapted from Luster et al, Nature Immunology 6, 1182–1190
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cell adhesion molecule (VCAM), and intercellular adhesion molecule (ICAM)-1), chemokines, inducible 
enzymes such as cyclooxygenase 2 (Cox-2) and inducible nitric oxide synthase (iNos), and growth factors 
[5, 6].  
 
2.1.2. Resolution of Inflammation 
  
Beside the importance of a tightly regulated initation of inflammation its termination is of equal 
importance since the persistent or prolonged exposure to injurious agents leads to the permanent 
presence of proinflammatory mediators. This results in chronic inflammation which is a hallmark of 
various diseases and autoimmunity.  
A prerequisite for resolution is the effective elimination of all “activating” contributors, including the 
removal of the initial stimuli, downregulation of proinflammatory gene expression, and the effective 
elimination of activated neutrophils. The latter is accomplished by the onset of programmed cell death 
leading to their specific recognition and clearance by macrophages [7]. Additionally important is the 
clearance of other inflammatory cells as well as excess resident tissue cells that have been driven to 
proliferate in response to repair mechanisms [8], making the process of apoptosis an indispensable event 
in the termination of inflammatory responses. 
In terms of inter- and intracellular signaling, the resolution phase is characterized mainly by the release of 
anti-inflammatory agents, including cytokines such as IL-4, IL-10, IL-13, Interferon-α (IFNα), as well as 
transforming growth factor β (TGFβ). At the beginning of the 21st century it has been shown that the 
transcription factor NF-κB is not only a potent initiator of inflammation but also plays an essential role in 
the resolution phase [9]. While its activation during the initiation of inflammation triggers pro-
inflammatory gene expression, its onset during resolution is associated with the expression of anti-
inflammatory genes. Hence, it is quite clear that the tight control of NF-κB signaling and the balance 
between pro-inflammatory genes and survival of cells, and the expression of anti-inflammatory genes are 
the main determinants for an appropriate cellular response to a diversity of challenging invaders. 
 
 
2.1.2.1. Role of negative feedback regulators in the resolution of inflammation 
 
Whereas the activation of inflammation is quite well understood its resolution and the involved regulatory 
molecules remain largely elusive. Meanwhile it is commonly accepted that the triggers of resolution are 
already set within the early stages of inflammatory processes. These include so called negative feedback 
loops that occur post induction and allow an unhindered first wave of activity before ensuring the 
organized termination of the NF-κB response [10, 11]. Well described negative feedback regulators 
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include the inhibitor of kappa B (IκB) and the de- and ubiqutinating enzyme A20 [12-14]. Feedback loops 
occur at all levels of signal transduction: at the receptor level, affecting all downstream events, at the 
level of signal transduction and individual transcription factors, leading to the selective silencing of genes, 
and also at the posttranscriptional level, preventing translation and promoting degradation of transcripts. 
The latter depends on the accessibility of cis-acting AREs situated in their 3’-UTR [15-17]. These elements 
account for effective destabilization and translational block of proinflammatory mediators regulated by 
specific ARE binding proteins. Generally, ARE-binding proteins either act in RNA stabilization, as it is the 
case for HuR [18], or in degradation, as already demonstrated for BRF1 and TTP [17, 19]. 
 
 
 
2.2. Tristetraprolin: an mRNA destabilizing protein 
 
TTP is the best studied member of a small family of proteins, the 12-O-tetradecanoylphorbol-13-acetate 
(TPA) inducible sequence 11 (TIS11) proteins. All TIS11-proteins function in the posttranscriptional 
regulation of genes exhibiting high turnover rates as cytokines, cell cycle regulators or transcription 
factors. The TIS-family consists of four members: TTP (also known as TIS11, ZFP36, GOS24 or Nup475), 
TIS11b  (Berg36,  ERF-1, BRF-1,  ZFP36L1),  TIS11d  (ERF-2, BRF-2, ZFP36L2)  and  the  fourth  member  
 
 
 adapted from Baou et al., Journal of Biomedicine and Biotechnology, 2009 
Fig. 2T: ARE-mediated 
mRNA decay by TIS11 
proteins. Binding of TIS-
proteins to ARE motifs in 
the transcript-3’UTR leads 
to the recruitment of 
deadenylases (hCcr4, 
PARN). Deadenylation 
subsequently results in 
either the recruitment by 
the exosome or decapping 
by hDcp1 and hDcp2. The 
exosome constitutes a 
multiproteincomplex 
containing exonucleases as 
Rrp4, Rrp40, Rrp41 and 
PM-Scl75, and triggers the 
3’-5’ directed RNA-decay. 
Conversely, decapping by 
hDcp1 and hDcp2 is 
followed by exunocleolytic 
5’-3’ decay facilitated by 
Xrn1. 
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ZFP36L3, whose expression was described in mouse placenta but was not detected in human tissues [20].  
All these proteins have been found to contribute to mRNA destabilization by either the exosome mediating 
3’-5’ RNA decay, or by exonculease activity, where XRN1 triggers the 5’-3’ degradation of the transcript 
[21]. Mode of action is thereby the binding of TIS-proteins to specific AREs in the 3’-UTR of the target 
mRNAs (Fig. 2T). ARE-binding is accomplished by a tandem-zinc-finger-structure, which appears to be the 
common feature of TIS-family proteins [22], since the spacing as well as the length of the linker between 
the tandem CCCH-zinc fingers is highly conserved. Although the analogy of the zinc-binding motifs 
accounts for a similarity in function, they exhibit differences in target affinity as well as a cell type specific 
regulation.  
TTP was first identified in the late 1980ies as an immediate early gene rapidly induced by phorbol 12-
myristate 13-acetate (PMA) [23-25], and a variety of other stimuli including serum, insulin, and growth 
factors [26-29] in different cell types, including fibroblasts, murine as well as human macrophages but 
also in monocytes, neutrophils, myeloid as well as in T-cells. The initial characterization of a tandem zinc-
finger structure, as well as its reported nuclear localization, initially led to the assumption that it might 
function as a transcriptional regulator [30-32]. However, in the meanwhile it is well established that TTP 
promotes AMD.  TTP was shown to  bind  to  a subset of AREs, and the nonamer UUAUUUAUU was 
identified as the minimal complete binding site [33]. The motif is recognized by the tandem CCCH-type 
zinc-finger domain of TTP, and the integrity of this domain has been shown to be indispensable for mRNA 
degradation, since a single mutation within either zinc-finger abolishes the ARE binding activity [34]. TTP 
exhibits no enzymatic activity itself but recruits various components of the basic mRNA decay machinery 
via its N- and C-terminal domains (Table 1T) [35, 36]. TTP interacts with decapping-complex-members as 
Dcp2, Dcp1a, Edc3 or Hedls via its N-terminal domain [36, 37]. In addition, TTP binds to Xrn1, a well 
described 5’-3’ exonuclease [36] as well as to Ago2 and Ago4, which comprise key regulators of the RNA-
induced silencing complex [38]. All these components colocalize together with TTP at so called 
“processing-bodies” (P-bodies), small cytoplasmic foci where specific mRNAs are recruited for either 
translational silencing by micro RNAs or mRNA decay triggered by AREs. A classical P-body-associated 
protein that binds to TTP is the deadenylase Ccr4. Moreover, it is reported that the enzyme Dicer, 
normally involved in the processing of miRNAs, is involved in TTP-mediated mRNA degradation, in 
addition to miR16 which contributes to mRNA destabilization through association with argonaute family 
members [38]. Thus, TTP and miRNAs codependently mediate RNA-decay by partly sharing the same 
processing pathways. Furthermore, TTP was found to be a component of the RNAi pathway in drosophila 
melanogaster [39]. Apart from that, TTP facilitates the 3’-5’-directed degradation of mRNAs by interacting 
with the exosomal subunits PM-Scl75 and Rrp4 [40], two of at least ten exonucleases that form, together 
with RNA binding proteins, the exosom-multiprotein-complex which accounts for coordinated processing 
and degradation of RNAs.  
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Table 1T: TTP-interacting proteins 
 
 
 adapted from Sandler & Stoecklin, Biochem. Soc. Trans; 2008 
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2.2.1. Importance of TTP phosphorylation 
 
ARE-motifs are not only important elements in the regulation of transcript decay, they also contribute to 
the stabilization of mRNAs when desired. This can be achieved by the competitive binding of RNA-
stabilizing and destabilizing proteins as HuR and TTP, respectively. Whereas destabilizers such as TTP 
account for the degradation of targets in unstimulated cells, they are squeezed out by stabilizing proteins 
and “inactivated” through posttranslational modifications to allow the rapid accumulation of mRNAs upon 
stimulation. The inhibition of AMD is controlled by various signaling pathways including the JNK, p38-
MAPK and PI3K (phosphoinositide-3-kinase) cascades [41-44]. It was described recently [45, 46] that 
p38-MAPK-MK2 signaling is of particular interest in terms of cytokine stabilization. MK-2 was shown to 
directly phosphorylate TTP at serine residues Ser52 and Ser178 after LPS stimulation in mouse 
macrophages [47], which allows binding of the adaptor protein 14-3-3 and further reduces the ability of 
TTP to destabilize mRNAs [48, 49]. In line with that, MK2-/- mice exhibit strongly reduced levels of known 
TTP mRNA targets such as IL-1, IL-6 and IFNγ [45, 46]. Furthermore, the double-knockout of MK2 and 
TTP results in the high TNFα levels observed in TTP-/- mice [50]. It is suggested that the phosphorylation 
mediated by MK-2 reduces the ARE-binding affinity of TTP and affects protein-protein interactions 
important for the recruitment of components of the RNA-decay machinery. While TTP “inhibition” is 
triggered by phosphorylation, dephosphorylation by the protein phosphatase 2A (PP2A) results in 
reactivation of its destabilizing ability. MK-2 seems to be counterbalanced by PP2A which is believed  to  
compete  with  the  adaptor  14-3-3  for  binding to TTP (Fig. 3T)  [51].  In addition to  p38-MK2  various 
 
       adapted from Sandler & Stoecklin, Biochem. Soc. Trans; 2008 
 
Fig. 3T: TTP controls ARE-mediated decay. TTP binds to ARE-motifs in the uninduced state and facilitates mRNA degradation. Upon extracellular 
stimulation, the onset of signaling cascades as the p38-MAPK-MK2, trigger the phosphorylation of TTP resulting in binding of the adaptor protein 14-3-3 
and stabilization of target mRNAs. In addition, phosphorylation stabilizes TTP itself, leading to its accumulation in the cytoplasm and its exclusion from 
stress granules. Finally, the phosphatase PP2A squeezes 14-3-3 out and causes dephosphorylation of TTP restoring the initial state. 
 
 
other kinases have been shown to phosphorylate TTP, but their functions remain largely elusive yet. 
Those kinases include the p42 MAPK, which accounts for posphorylation of Ser220 in mouse TTP [52] and 
the p38α and -β isoforms which are involved in multiple phosphorylation events [53]. In addition, 
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MALDI/MS analysis revealed various phosphorylation sites of human TTP including Ser66, Ser88, Thr92, 
Ser169, Ser186, Ser197, Ser218, Ser276, Ser296 [54]. The related kinases such as protein kinase A (PKA), 
protein kinase C alpha (PKCα), protein kinase C beta (PKCβ), protein kinase C gamma (PKCγ), protein 
kinase C zeta (PKCζ) and inhibitor of kappa B kinase 1 (IKK1),  glycogen synthase kinase-3 (GSK-3) as 
well as extracellular-signal-regulated kinase 1 (ERK1) were predicted bioinformatically. However, not all 
TTP-kinases alter its function as a destabilizing protein as supported by a study using a series of TTP-
mutants, wherein the single mutations of serines and/or threonines showed that phosphorylation events 
must not necessarily impact its mRNA-degrading function [55].  
 
Initially, the biological function of Tristetraprolin was uncovered by the creation and analysis of TTP 
knock out mice. They exhibit classical inflammatory signs as spontaneous arthritis, cachexia, neutrophilia 
and dermatitis [56]. Careful analysis of these mice and isolated cells revealed that these symptoms are 
caused by the extensive overproduction of the cytokine TNFα, a principal mediator of inflammation in 
acute and chronic inflammatory diseases [57]. Likewise, mutations in TTP have been associated with 
autoimmune diseases in humans [58]. While the transcription of TNFα is not affected in macrophages 
obtained from TTP k.o mice its mRNA half-life is prolonged, which was the initial observation leading to 
the identification of the first TTP-mRNA target [19]. Beside TNFα, the turnover of several other mRNAs is 
controlled by TTP, including GM-CSF, Cox-2, Ier3 as well as the interleukins -2, -3, -6 and -10 [19, 59-61].  
 
 
 
2.3. NF-κB signaling 
 
One of the main signaling pathways triggered by e.g. the proinflammatory cytokine TNFα is the NF-κB 
pathway. The complexity of the NF-κB response is reflected by a great diversity of different effects of NF-
κB activation, which is due to the fact that varying heterodimer combinations of the transcription factor 
subunits can regulate different sets of genes. NF-κB target genes can be grouped into different classes 
and regulate diverse biological responses. The most important role of NF-κB is its function in innate and 
adaptive immunity, including not only the proinflammatory gene expression of cytokines, chemokines and 
related receptors but also the regulation of antiapoptotic genes. Beside the general accepted role NF-κB 
plays in the balance between cell survival and cell death, it additionally accounts for the expression of 
genes which are important regulators of differentiation and proliferation. Since during the NF-κB 
activation cascade various stimuli trigger effectors that signal to one single transcription factor, 
dysregulation of its function is implicated in several pathophysiological situations (e.g. [62-64]). 
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2.3.1. Canonical versus non-canonical NF-κB signaling 
 
Generally, two signaling pathways lead to the activation of the transcription factor NF-κB, the classical or 
canonical pathway on the one hand, and the alternative, also called the non-canonical pathway, on the 
other hand. In both cases signaling events start with receptor engagement leading to the onset of 
receptor-specific proximal cascades that finally converge at the inhibitor of kappa B (IKK)-signalosome. 
Activation of the latter triggers the release and subsequent activation of NF-κB subunits. These consist of 
either hetero- or homodimers of different combinations of the five members of the NF-κB-transcription 
factor family, p50, p52, p65/RelA, c-Rel, and RelB.  During the onset of the canonical pathway (Fig. 4T, 
left), receptor ligation leads to the recruitment of adaptor proteins such as TNF receptor-associated 
factors (TRAFs; see 2.3.3) which in turn activate the IKK-complex leading to phosphorylation and 
subsequent degradation of the inhibitory protein IκBα. The IKK-multiprotein-complex contains two kinase 
subunits, namely IKKα (IKK1) and IKKβ (IKK2) as well as the non-catalytic regulator subunit IKKγ (NEMO) 
(Fig. 5T, bottom) [65]. Activated through upstream incoming signals, mainly IKKβ accounts for 
phosphorylation of IκBα on Ser32 and Ser36 and of Ser19 and Ser23 of IκBβ. Phosphorylation is a 
prerequisite for K48-linked polyubiquitination, which targets the IκB protein for proteasomal degradation. 
This results in released NF-κB dimers, which subsequently translocate to the nucleus. The classical 
pathway leads to the activation of NF-κB dimers consisting of different combinations of the subunits p65, 
p50, c-Rel and RelB. However, the most common and best studied combination constitutes the p65/p50 
heterodimer. Its activation is achieved by a variety of proinflammatory signals including IL-1, TNFα and 
LPS and leads to the expression of genes encoding cytokines, adhesion molecules, enzymes as well as 
antiapoptotic mediators [66].  
                                                   
Fig. 4T: Comparison of canonical 
(left) and non-canonical (right) 
NF-κB activation.  
Left: Inducers such as TNFα, IL-1 or 
LPS lead to receptor recruitment of 
adaptor proteins that trigger the 
activation of the IKK-complex 
consisting of IKKα, IKKβ and IKKγ 
(NEMO). This results in 
phosphorylation and degradation of 
IκBα resulting in the release of the 
p65/p50 heterodimer, its 
translocation to the nucleus and the 
onset of transcription. Right: 
Receptor activation results in NIK 
activation which activates the IKK-
complex consisting of an IKKα 
homodimer. Subsequent activation of 
p52/RelB is IκB-independent and 
results from the processing of the 
p52 precursor p100. 
adapted from www.abcam.com
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The alternative pathway is induced by factors such as lymphotoxin B and the B cell activating factor 
(BAFF) that activate the NF-κB-inducing kinase (NIK). This results in the phosphorylation of an IKK-
complex that comprises solely two IKKα subunits in this case (Fig. 4T, right). Activation of the p52/RelB 
heterodimer is IκB-independent and achieved through phosphorylation and processing of the p52 
precursor p100 [67, 68].  
 
All NF-κB-family members comprise an N-terminal Rel-homology domain (RHD), responsible for 
homo- and heterodimerization and DNA-binding. NF-κB dimers bind to κB binding motifs in various 
promoters, recruit either coactivators or corepressors and specifically regulate gene expression. A main 
structural difference between the five members is the C-terminal regulatory domain. While p65, RelB, as 
well as c-Rel own transcriptional activation domains (TADs), responsible for the positive regulation of 
transcription, the subunits p50 and p52 lack TADs and act in the inhibition of promoter activity unless 
they become associated with a TAD-containing NF-κB-subunit (Fig. 5T, left). The three typical IκB 
proteins IκBα, IκBβ, IκBε, characterized by so called ankyrin-repeat domains (Fig. 5T, right), are crucial 
for  keeping  NF-κB dimers  inactively  in the cytoplasm. The prototypic inhibitor IκBα for example, masks  
 
     
 
 
 
Fig. 5T: Schematic representation of the NF-κB (left), IκB (right) and IKK (bottom) protein families. Posttranslational modifications are 
indicated with P (phosphorylation), Ac (acetylation), Ub (ubiquitination); inhibitory events are represented by red colour. RHD, Rel homology domain; 
TAD, transactivation domain; LZ, leucine zipper domain; GRR, glycine-rich region; DD, death domain; HLH, helix-loop-helix domain; Z, zinc finger; NBD, 
NEMO-binding domain; CC1/2, coiled coil domains; MOD/UBD, minimal oligomerization domain and ubiquitin-binding domain. 
 
 
adapted from Hayden et al., Cell 2006
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the nuclear localization signal (NLS) of p65 whereas the NLS of the p50 subunit is left exposed resulting in 
the constitutive nuclear-cytoplasmatic shuttling  [69, 70] of the IκBα/NF-κB complex. Finally, degradation 
of IκBα leads to unmasking of the p65 NLS, enabling its nuclear translocation. p65 contains a classical 
monopartite NLS, characterized by a stretch of 4-6 basic amino acid residues, and it has been shown that 
the karyopherin importin α3 specifically binds the p65-NLS [71], whereas importin β is responsible for 
docking to the nuclear pore complex (NPC). Nevertheless, it is not well established so far how nuclear 
shuttling of the known diversity of transcription factors is selectively timed and regulated. However, the 
variety of differently structured NLS’ is known to contribute to the specific recognition by various 
karyopherins [72, 73]. The nuclear localization and accumulation of NF-κB dimers is prerequisite for 
transcriptional activation: they bind to the κB consensus sequence 5’GGGRNWYYCC3’ (N-any base; R-
purine; W-adenine or thymine; Y-purimidine) [74] of promoters and the high sequence variability of the 
κB binding motif in combination with  differences of  NF-κB-dimer  affinities  is  one  of  the   main 
explanations for the high diversity of NF-κB regulated genes [75, 76]. 
 
 
2.3.2. Role of posttranslational modifications in the activation of NF-κB 
 
Beside the tight regulation of p65 nuclear import, further activation of NF-κB is achieved through post 
translational modifications, recruitment of coactivator proteins, increased stabilization and the coordinated 
interaction with the basal transcriptional apparatus as well as the epigenetically regulated accessibility of 
promoter binding sites (Fig. 6T). Various kinases have been described to phosphorylate p65 at different 
serine residues present in the RHD and TADs of the transcription factor (Fig. 6T, right). PKA for example, 
mediates phosphorylation of Ser276 of p65 promoting its interaction with the coactivating histone-acteyl-
transferases CBP (cyclic adenosine monophosphate responsive element-binding protein (CREB)-binding-
protein) and p300 [77, 78]. In addition, the nuclear kinases MSK1 and MSK2, which are activated by 
multiple pathways containing components as the MAPKs ERK and p38, account for Ser276 phosphorylation 
and also contribute to enhanced transcriptional activity [79]. Furthermore PKCζ phosphorylates Ser311 of 
p65 also mediating the interaction with CBP, [80] and CKII inducibly phosphorylates Ser529 but  it  is  still  
unclear  whether  this modification  has an effect  on transcription  [81, 82]. Beside phosphorylation, also 
other posttranslational modifications are indispensable for full activation of NF-κB-mediated transcription.  
CBP/p300 mediated acetylation  of p65 at Lys310 leads to highly increased transcriptional activity [83] and 
depends on the prior phosphorylation of Ser276 [77, 84]. The IKK-signalosome members IKKα and IKKβ 
play an interesting role in the p65 phosphorylation-acetylation process. They have been shown to directly 
phosphorylate Ser536 of p65, which significantly enhances p65 Lys310 acetylation [77, 84, 85]. Ser536 
phohsphorylation  is  believed  to alter the interaction of p65 with the SMRT (silencing mediator of retinoic  
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acid and thyroid hormone receptor)-complex resulting in decreased levels of histone-deacteylases as 
HDAC3, finally promoting an interaction with CBP/p300. An additional important aspect is that IKKα not 
only acts on p65 but also directly phosphorylates the SMRT-itself [86], is associated with κB sites in 
promoters of diverse NF-κB-target genes, and is involved in the phosphorylation of histone H3 on Ser10 
[87, 88]. Furthermore, IKKα has been associated with phosphorylation of the CBP/p300 coactivator 
complex [89]. Although phosphorylation events resulting in the recruitment of nuclear coactivators as 
CBP/p300 are the most critical step in building an “enhanceosome” to modulate general levels of gene 
expression, other signaling pathways and transcription factors, such as activator protein 1 (AP-1, 
composed of Fos (c-Fos, FosB, Fra-1, Fra-2) and Jun (c-Jun, JunB, JunD) family members [90], CREB or 
CCAAT enhancer binding protein (C/EBP) act in cooperation with NF-κB to facilitate a tightly regulated 
response to the diversity of incoming signals [91]. 
 
 
2.3.3. Interplay of NF-κB and MAPK signaling and the importance of Ubiquitination 
 
Since various stimuli trigger the activation of NF-κB, there is a remarkable diversity of protein components 
of different pathways triggering signals that finally culminate on the level of the IKK-signalsome. 
However, several activating components upstream of the IKK-complex are shared by these signaling 
pathways. Two main actors are the receptor-interacting proteins (RIPs) and TRAF protein families that 
efficiently activate IKKs (Fig. 7T). RIPs are classical adaptor proteins that interact with other adaptors as 
TRADD (TNF receptor-associated death domain) and FADD (fas-associated death domain) at the 
cytoplasmic part of the receptor. RIP proteins furthermore build a complex with TRAF-proteins, which is 
prerequisite for the onset of downstream kinases and successful IKK activation. RIP family members are a 
adapted from Hayden et al., Cell 2006 adapted from Schmitz et al., ChemBioChem, 2004 
Fig. 6T: Posttranslational modifications regulate NF-κB 
transcriptional activity. Left: A) in the uninduced state, κB 
elements are occupied by p50 or p52 homodimers, transcription is 
repressed. B) stimulation leads to release  of  NF-κB dimers, 
phosphorylation of p65 by various kinases and the recruitment  of the  
the  CBP/p300  coactivator  complex  which  facilitates p65 acetylation  
 and promotes target gene expression. C) IKKα catalyzes the exchange of corepressor – coactivator complexes, by phosphorylation of both the coactivator complex CBP/p300 as well as corepressor complexes leading to HDAC release. D) MSK and IKKα promote transcriptional activation through 
histone phosphorylation. E) IκB proteins are involved in both positive and negative regulatory mechanisms: Bcl-3 and IκBζ promote or repress 
transcription by interacting with p50- and p52-containing complexes. IκBα and IκBε sequester NF-κB dimers away from DNA and act as negative 
regulators. Right: Summary of inducible phosphorylation sites within p65, related kinases as indicated. 
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Fig. 7T: Simplified TNFR-
activated NF-κB signaling. 
Receptor ligation leads to recruitment 
of TRAF/RIP complexes which 
facilitate activation of the IKK-
signalosome, resulting in 
phosphorylation and degradation of 
IκBα und subsequent release of 
p65/p50 and its translocation into the 
nucleus. 
general hallmark of TRAF-dependent pathways as exemplified by the TNFR 
superfamily signaling cascades (Fig. 7T). Seven different TRAF proteins 
have been identified so far. They share a C-terminal TRAF-domain, 
mediating protein-protein interactions, and all of them, with the exception 
of TRAF1, contain N-terminal RING finger domains that function as E3 
ubiquitin ligases catalyzing the ubiquitin-transfer to target proteins. 
Ubiquitination is a process where ubiquitin is first activated by an   
activating enzyme (E1) that forms an intermediate complex with a 
ubiquitin conjugating enzyme (E2). Activated ubiquitin-chains are finally 
transferred onto lysine residues of target proteins by E3-ubiquitin-ligases. 
The ubiquitination-process is an essential regulatory, posttranslation event 
that accounts for the tightly coordinated and timed transmission of signals 
between proteins. Whereas lysin-48 (K48)-linked ubiquitination is 
responsible for 26S-proteasomal degradation, the lysine-63 (K63)-linked 
ubiquitination of various 
signaling mediators has been implicated in the specific regulation of signal 
transmission leading to either activation or inhibition of NF-κB [92, 93]. 
Whereas for example the de- and ubiquitinase A20 acts, beside IκBα, as 
the most prominent negative feedback inhibitor of NF-κB, TRAF-E3-Ligase 
activity plays an important role in the activation of the IKK complex [92]. 
Importantly, TRAFs are also indispensable for regulating other pathways, as the JNK cascade leading to 
AP-1 activation, and are therefore important mediators for the crosstalk of various signaling cascades 
activated by TNFR superfamily members. In the case of TNFR1 engagement, TRAF2 interacts with TRADD 
[94] at the receptor and facilitates, through recruitment of receptor-interacting protein (RIP) and TGFβ 
activated kinase 1 (TAK1) the activation of the IKK-complex. Interestingly, TRAF2-/- cells exhibit normal 
TNF mediated activation of NF-κB but exert deficiencies in AP-1 activation [95] pointing at the importance 
of TRAF2 in the regulation of signals that lead not only to NF-κB, but also to the activation of AP-1. 
MAPKs and IKK-Ks (inhibitor of κB kinase kinase) are the commonly known upstream kinases that account 
for AP-1 and NF-κB activation, respectively. After TNFR stimulation, these pathways are concomitantly 
activated and share common regulatory proteins until the level of MAP3Ks but at this point they diverge 
(Fig. 8T). The outcome of receptor engagement on the biological level ranges from cell survival to cell 
death and includes influences on gene expression, differentiation, adhesion, cell metabolism and motility 
[90]. Importantly, activation of IKK proceeds faster than the onset of MAPK, which accounts for the tight 
temporal separation of IKK and MAPK signaling and is therefore the basis for the ability to control the life-
or-death decision in TNFα induced cells. Two of the main MAP3Ks that account for JNK activation are 
TAK1 and  MEKK1. TAK1  is  a  MAP3K  that  was  initially  found activated upon TGFβ treatment [96] and 
adapted from Hayden et al., Cell 2006 
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Fig. 8T: TNFR-induced, concomitant activation of MAPK 
and NF-κB signaling. Receptor engagement leads to TRAF-
recruitment and facilitates activation of MAP3Ks. Subsequent 
phosphorylation events result in either MAPK or IKK activation. 
studies of TAK1-/- fibroblasts revealed defective NF-κB, JNK as well as p38 activation after TNFα 
stimulation [97]. In addition TAK1-/- B-cells show reduced proliferation, and ablated NF-κB activation after 
Toll-like-receptor (TLR) stimulation [97], TAK1-deficient T-cells exhibit impaired JNK as well as NF-κB 
signaling, but neither B nor T-cells show any response after TNFR family member-activation [98]. Based 
on this, the role of TAK1 is receptor as well as cell-type dependent. On the molecular level, TAK1 interacts 
with the TAK-binding proteins 1 and 2 (TAB1/2) [99, 100], which facilitate binding to TRAF6, finally 
allowing the recruitment to the receptor complex via 
interaction with RIP.  
MEKK1 is a 196kD protein with dual function. It 
displays catalytic activity, which is attributed to the 
kinase domain on its C-terminus, as well as E3-Ligase 
activity, due to a ring finger motif at the N-terminus. 
The kinase activity is directed against downstream 
targets as MKK 3, 4, 6, and 7, MAP2Ks that mediate 
p38 and JNK activation [101]. The ring finger domain 
of MEKK1 mediates K-63-linked autoubiquitination of 
the protein after CD40 receptor stimulation in B-cells, 
stabilizing its interaction with other proteins [102]. 
Intriguingly, self-ubiquitination of MEKK1 strongly 
depends on an intact kinase domain and on the 
presence of TRAF2 as well as the E2-Ligase Ubc13 [102, 103]. It has to be noted that the recruitment of 
MEKK1 to the membrane-associated TNFR-superfamily-member-CD40-receptor complex is dependent on 
IKKγ but not on autoubiquitination [103]. In this case K63-linked ubiquitination is subsequent to the 
dissociation of the protein from the receptor complex. Basically, MEKK1 is implicated in TNF-mediated 
signaling to JNK which was unraveled by the careful analysis of cells obtained from MEKK1-/- mice, 
showing that MEKK1 plays an important role in TNF signaling, as activator of both p38 and JNK, but has 
no effect on IKK and NF-κB activation [104-107]. The signaling mechanism that forms the basis for the 
concomitant onset of MAPK and IKK-Ks, was well described recently by a study carried out in CD40 
induced B-cells (Fig. 9T) [103]. Both, CD40 as well as TNFR1, belong to TNFR superfamily of proteins that 
transmit signals by utilizing TRAF proteins as intermediate adaptors to phosphorylate downstream 
effectors. Upon CD40 receptor engagement the TRAF-proteins TRAF2 and TRAF6 undergo K63-linked 
autoubiquitination, which promotes the recruitment of the E3-ligases cIAP1/2, as well as TRAF-3 and the 
MAP3Ks MEKK1 and TAK1, resulting in a receptor-associated signaling complex. Both TRAF2 and TRAF6 
exhibit E3-Ligase activity and mediate the K63-linked ubiquitination of cIAP1/2 resulting in their activation 
and the subsequent K48-linked ubiquitination of TRAF3 targeting this adaptor for proteasomal 
degradation. This destroys the “brake” and results in the release of the signaling complex into the cytosol. 
adapted from Karin & Gallagher, Immunological Reviews 2009
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Fig. 9T: CD40-receptor engagement induces “two-stage” MAPK 
signaling.  1) MAPK-signaling members in the uninduced state. 2) TNFR 
ligation recruits TRAF2, 3, 6 to the receptor. 3) TRAF2 and TRAF6 are 
autoubiquitinated resulting in cIAP1/2 ubiquitination and activation. MEKK1 and 
TAK1 are recruited via the inhibitor of nuclear factor κB kinase γ (IKKγ); TRAF3 
acts as “brake”. 4) cIAP1/2 mediate K48-linked ubiquitination of TRAF3 leading 
to its degradation and the release of TRAF2-MEKK1 and TRAF6-TAK1 signaling 
complexes to the cytosol. Complex transclocation is prerequisite for proper 
activation of signaling cascades leading to the onset of p38 and JNK. 
The “translocation”-step is prerequisite for MEKK1 and TAK1 autophosphorylation leading to JNK and p38 
MAPK activation. This so called “two-stage-activation mechanism” is described as specific feature of MAPK 
activation and does not hold true for the onset of the IKK complex. The signalosome is activated as soon 
as receptor recruitment occurs and is released to the cytosol independent of cIAP1/2 and the proteasome 
[103]. This timed difference between a “two-
step MAPK” activation, which occurs with 
much slower kinetics compared to the rapid 
induction of the IKK-NF-κB pathway, ensures 
in the first instance the onset of a “cell-
survival-programme” and concomitantly 
prevents prolonged p38 and JNK activation 
which promote the “cell-death-programme”. 
Therefore, the tightly controlled balance 
between NF-κB and MAPK signaling is 
indispensable for the requested response to 
TNFR stimulation. TNFα represents therefore 
a proinflammatory cytokine with the 
additional optional capacity to induce cell 
death. 
 
 
 
Here we show that TTP attenuates NF-κB activity independently from its ability to destabilize mRNAs 
in human and murine cells. We demonstrate that TTP interferes with NF-κB activation at least in part by 
impairing nuclear translocation of p65 leading to the selective regulation of NF-κB dependent gene 
expression. Furthermore, we find TTP implicated in the TNFα induced onset of apoptosis, which is most 
probably regulated by the interplay with MEKK1 and the JNK signaling cascade. These findings reveal a 
previously unknown “dual-function” of TTP and suggest that this protein might play a broader role in the 
regulation of diverse cellular processes. 
 
 
 
 
 
 
 
 
adapted from Karin & Gallagher, Immunological Reviews 2009
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3. RESULTS 
 
 
 
3.1. Tristetraprolin is an immediate early inducible, hyperphosphorylated,  
       cytoplasmic protein in HUVEC 
 
 
The endothelium acts as a critical barrier between blood stream containing immune cells and the 
underlying tissues and therefore constitutes an important hallmark in the regulation and control of 
inflammatory processes. The disturbance of its functional integrity in response to mechanical, chemical or 
immunologic injuries promotes both local as well as systemic inflammation. Therefore, the tight genetic 
and molecular regulation is of great importance to facilitate a quick and appropriate response to injury.  
In search of potential molecular contributors to the regulation of inflammation in HUVEC, we found that 
the mRNA binding and degrading protein Tristetraprolin is induced by the proinflammatory agents LPS, IL-
1 as well as TNFα in endothelial cells (Fig. 10T). LPS treatment of HUVECs resulted in the accumulation of 
TTP mRNA reaching a maximum 90 minutes after stimulation (Fig. 10T, left) whereas IL-1 as well as 
TNFα induction lead to a quite rapid response within 30 minutes, followed by the fast drop of TTP mRNA 
levels reaching the uninduced basal levels after around 150 minutes of cytokine-treatment (Fig. 10T, 
middle and right). 
 
 
 
 
Fig. 10T: Tristetraprolin exhibits immediate early kinetics induced by proinflammatory agents in HUVECs. Real-time PCR analysis of LPS 
(left), IL-1 (middle) and TNFα (right) induced HUVECs after indicated time points is shown. Depicted are relative TTP expression levels normalized to 
β2-microglobulin. 
 
 
Subsequently, we analyzed TTP protein levels in TNFα induced HUVECs and found that it mimics mRNA 
behaviour in terms of rapid immediate induction. Interestingly, whereas TTP mRNA levels declined quite 
fast, the protein accumulated over a period of around 3 hours (Fig. 11T, A). Importantly, we observed a 
molecular weight shift of the protein on the Western Blot which has been previously attributed to 
phosphorylation. Obviously, this posttranslational modification is associated with the accumulation of TTP 
in HUVEC, which could be indicative of stabilization (Fig. 11T, A, bottom panel). Interestingly, protein 
levels started to decrease after 3 hours of induction and decreased below detection limit after 6 hours; 
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this decline could be prevented by the addition of the proteasome inhibitor MG132 (Fig. 11T, B, 180 min 
time point). To determine the subcellular localization of TTP and therefore its potential site of action we 
analyzed cytoplasmic and nuclear fractions of HUVECs after TNFα stimulation. We could not detect any 
TTP protein in the nucleus, neither under unstimulated nor under induced conditions (Fig. 11T, C). 
 
 
 
 
 
 
So-called immediate early response genes (IEGs) are generally known to be activated transiently and 
rapidly in response to a wide variety of cellular stimuli and were found to be regulators of different cellular 
processes including cell growth and differentiation. Examples include transcription factors, secreted 
proteins, cytoskeletal proteins as well as receptor subunits.  
In the context of inflammation the early synthesis of proteins functions as gateway to the activation of 
late response genes, which is indispensable for a proper, timed resolution of the process in order to 
prohibit prolonged, chronical inflammation.  
Since most proinflammatory signals activate cascades leading to the onset of the transcription factor NF-
κB we aimed to determine whether the immediate early gene TTP is able to act as a negative feedback 
regulator of the TNFα mediated NF-κB-response. 
 
 
 
3.2. Tristetraprolin impairs NF-κB/p65 nuclear translocation [108]  
     published in JBC VOL. 284, NO. 43, pp. 29571–29581, October 23, 2009  
Fig. 11T: Rapid accumulation of posttranslationally 
modified TTP in the cytoplasm.  
A) top panel:  Real time PCR analysis of TNFα induced 
HUVECs, time points as indicated. Shown are relative TTP 
mRNA expression levels normalized to β2-microglobulin; 
bottom panel: Western Analysis of TTP protein levels in 
whole cell extracts prepared from the samples used for 
real-time PCR. 
B) HUVEC were treated with TNFα for the indicated time 
points in the presence or absence (control) of the 
proteasome inhibitor MG132 (10µM). Whole cell lysates 
were analyzed for the presence of TTP by Western 
Blotting. 
C) Cytoplasmic (CE) and nuclear (NE) extracts of TNFα 
induced HUVECs (time points as indicated) were subjected 
to Western Blotting and analyzed for subcellular 
localization of TTP.  
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Tristetraprolin (TTP) is a prototypic family 
member of CCCH-type tandem zinc-finger 
(TZF) domain proteins that regulate mRNA 
destabilization in eukaryotic cells. TTP 
binds to AU-rich elements (AREs) in the 
3´-UTR of certain mRNAs, including TNFα, 
GM-CSF and Ier3, thereby facilitating their 
ARE-mediated decay (AMD). Expression of 
TTP is upregulated by a variety of agents 
including inflammatory mediators such as 
TNFα, a prominent activator of the nuclear 
factor (NF)-kappaB (NF-κB) family of 
transcription factors. Accordingly, TTP is 
involved in the negative feedback 
regulation of NF-κB through promoting 
mRNA degradation. We describe here a 
novel, AMD-independent function of TTP 
on the termination of NF-κB response: TTP 
suppresses the transcriptional activity of 
NF-κB dependent promoters independent 
of its mRNA destabilizing property. In TTP 
knock out (k.o) mouse embryonic 
fibroblasts (MEF) lack of TTP leads to 
enhanced nuclear p65 levels, which is 
associated with the upregulation of 
specific, ARE-less NF-κB target genes. We 
find that attenuation of NF-κB activity is at 
least in part due to an interference of TTP 
with the nuclear import of the p65 subunit 
of the transcription factor. This novel role 
of TTP may synergize with its mRNA 
degrading function to contribute to the 
efficient regulation of proinflammatory 
gene expression. 
 
Tristetraprolin (TTP) was first identified in 
the late 1980ies as an immediate early gene 
rapidly induced by phorbol 12-myristate 13-
acetate (PMA) (1-3), and a variety of other 
stimuli including serum, insulin, and growth 
factors (4-7). The finding that this 
phosphoprotein is composed of a tandem zinc-
finger structure, as well as its reported nuclear 
localization, initially led to the assumption that it 
might function as a transcriptional regulator (8-
10). However, investigations over the last 
decade  have  demonstrated  that  TTP  binds to  
and accelerates the degradation of mRNAs 
exhibiting high turnover rates (e.g. cytokines, 
growth factors or proto-oncogenes) (11,12). 
These mRNAs are characterized by AU-rich 
element (ARE) motifs in their 3’-UTRs that serve 
as docking sites for RNA binding proteins.  TTP 
was shown to bind a subset of these AREs, and 
the nonamer UUAUUUAUU was identified as the 
minimal complete binding site (13). The motif is 
recognized by the tandem CCCH-type zinc-finger 
domain of TTP, and the integrity of this domain 
has been shown to be indispensable for mRNA 
degradation, because a single mutation within 
either zinc-finger abolishes the ARE binding 
activity (14). TTP exhibits no enzymatic activity 
itself but recruits various components of the 
basic RNA decay machinery via its N- and C-
terminal domains (15,16). The degradation of 
ARE containing mRNAs is regulated mainly by 
extracellular cues. Typically, TTP target mRNAs 
are rapidly degraded in unstimulated cells, but 
become transiently stabilized in response to 
activation. Several signaling pathways were 
shown to be involved in the control of AMD 
including p38-MAPK-MK2, which accounts for 
direct phosphorylation of mouse TTP in response 
to LPS. Importantly, this phosphorylation 
stabilizes the TTP protein but abrogates its 
ability to degrade mRNAs, resulting in the 
accumulation of the known target TNFα (17-19). 
TNFα, a principal mediator of inflammation in 
acute and chronic inflammatory diseases (20), is 
upregulated in TTP k.o mice, leading to a 
complex syndrome of inflammatory arthritis 
(21). Likewise, mutations in TTP have been 
associated with autoimmune diseases in humans 
(22). In addition to TNFα, the turnover of 
several other mRNAs is controlled by TTP, 
including GM-CSF, Cox-2, Ier3 as well as the 
interleukins -2, -3, -6 and -10 (11,12,23,24). 
One of the main signaling pathways triggered by 
TNFα is the NF-κB pathway. NF-κB comprises a 
family of transcription factors  (p65 (RelA), c-
Rel, RelB, p50 (NF-κB1), p52 (NF-κB2)) that 
form homo- and  heterodimers, as well as the 
inhibitory subunits IκBα, -β, -ε.  Engagement of 
TNF  receptor   superfamily  members  leads   to   
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 284, NO. 43, pp. 29571–29581, October 23, 2009 
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the activation of the classical NF-κB signaling 
cascade via recruitment of adaptor proteins 
(FADD, TRADD and TRAFs) to the cytoplasmic 
part of the receptor complex (25). The TRAF/RIP 
complex subsequently recruits and activates 
TAK1, leading to further activation of the IκB 
kinase (IKK) complex (26). IKKs in turn 
phosphorylate IκBs, thus promoting their 
ubiquitination and subsequent degradation by 
the 26S proteasome. This results in unmasking 
of the NF-κB/p65 nuclear localization signal 
(NLS), enabling its nuclear translocation. p65 
contains a classical monopartite NLS, which is 
characterized by 4-6 basic amino acid residues, 
and it has been shown that the karyopherin 
importin α3 specifically binds the p65-NLS (27), 
whereas importin β is responsible for docking to 
the nuclear pore complex (NPC). Nevertheless, it 
is not well established so far how nuclear 
shuttling of the known diversity of transcription 
factors is selectively timed and regulated, but 
the variety of differently structured nuclear 
localization signals is known to contribute to the 
specific recognition by various karyopherins 
(28,29).  
Beside the tight regulation of p65 nuclear 
import, further activation of NF-κB is achieved 
through post translational modifications. For 
example, phosphorylation of serine-threonine 
residues in either the N-terminal Rel homology 
domain (RHD) of p65, which accounts for 
dimerization and DNA binding, or the C-terminal 
transcriptional activation domains (TA1 and 
TA2), is linked to enhanced binding of co-
activator proteins, increased nuclear localization 
and stability, as well as to supporting the 
connection with the basal transcriptional 
apparatus (reviewed in (30)). In addition, other 
signaling pathways and transcription factors, 
such as activator protein-1 (AP-1), cyclic 
adenosine monophosphate responsive element-
binding protein (CREB) or CCAAT enhancer 
binding protein (C/EBP) often act in cooperation 
with NF-κB to contribute to the expression of 
inflammatory genes. Furthermore, the 
recruitment of nuclear co-activators, mainly 
acting on chromatin relaxation (e.g. the histone 
acetyltransferases CREB binding protein (CBP) 
and p300 and the nuclear kinase MSK1), is a 
critical step in building an “enhanceosome” to 
modulate general levels of gene expression (31). 
We show here that TTP attenuates NF-κB 
activity independently from its ability to 
destabilize mRNAs in human and murine cells. 
Further we demonstrate that TTP interferes with 
NF-κB activation at least in part by impairing 
nuclear  translocation of p65  leading to the 
selective  regulation  of  NF-κB  dependent gene  
expression. These findings reveal a previously 
unknown function of TTP and suggest that this 
protein might play a broader role in the 
regulation of diverse cellular processes. 
 
Experimental Procedures 
 
Plasmid Constructs - Reporter plasmids 
5xNF-κB-luc, p53-luc, NFAT-luc, pFR-luc were 
obtained from Stratagene (PathDetect). Il-8-luc, 
the truncated version of the IL-8 promoter, TF-
luc as well as expression vectors for p65, IKK2 
and TAK1 have been described elsewhere (32-
34). TAB1 was purchased from Invitrogen. The 
Gal4-p65 mutant constructs (p65*: p65 aa286-
551; M1: p65 aa286-520, M2: p65 aa521-551; 
M3: p65 aa450-520) were kind gifts from L. 
Schmitz (35) as well as the pRC/CMVp65 
plasmid used for generation of p53NLSΔNLSp65: 
briefly, a synthetic p53NLS linker (5’HindIII-
3’NcoI) was fused to the N-terminus of p65. The 
p65 NLS sequence was excised by BstEII-AleI 
restriction and exchanged with the 
corresponding fragment from the 
pCDNA3.1/Myc-Hisp65NLSmut vector kindly 
provided by R. Fagerlund (27). The expression 
plasmids for SV40NLSp65 and SV40NLSΔNESp65 
were gifts from Shao-Cong Sun (36). Human 
mycTTP was generated by PCR from the RZPD 
clone IRAK p961M0614Q2 and ligated into the 
EcoRI/SalI sites of pCMV-myc (Clontech). 
MycTZF (aa97-173) and mycC124R were 
generated by subcloning and in vitro 
mutagenesis, respectively. Oligonucleotide 
sequences are shown in Supplementary Table 1. 
The integrity of all constructs generated by PCR 
was confirmed by sequencing. Expression 
plasmids for TRAF2, CBP/p300 and pRSGFP-C1-
NFATc were kindly provided by H. Wajant, 
C.Brostjan and L.Gerace, respectively. 
Cell culture and transfections - HEK 293 cells 
and HeLa cells were obtained from ATCC, wild-
type (wt) and TTP k.o MEF were kindly provided 
by PJ Blackshear. Cells were cultured in DMEM 
(Bio-Whittaker) supplemented with 10% FCS 
(Sigma), 2mM L-glutamine (Sigma) penicillin 
(100units/ml) and streptomycin (100µg/ml). 
Human umbilical vein endothelial cells were 
isolated from umbilical cords as described (37) 
and maintained in M199 medium (Lonza) 
supplemented with 20% FCS (Sigma), 2mM L-
glutamine (Sigma), penicillin (100U/ml), 
streptomycin (100µg/ml) and 0.25µg/ml 
fungizone, 5U/ml Heparin and 25µg/ml ECGS 
(Promocell).  HEK 293 cells were transfected by 
the calcium phosphate method as described 
(38). MEF as well as HUVEC were transfected 
using  the  polyethylenimine  (PEI) method (39). 
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siRNA mediated knock down of TTP was 
performed using the Stealth® custom siRNA 
pool for TTP (Invitrogen). The sequences are 
given in Supplementary Table 1.  
Reporter Gene Assays - HEK 293 cells were 
grown in 24-well plates, MEF and HUVEC in 12-
well plates. Cells were transfected as described 
with the indicated reporter and/or expression 
plasmids using 4µg total DNA. Cells were 
stimulated with TNFα (10ng/ml) for 16hrs prior 
to harvesting. All experiments were performed in 
triplicates, and are representative for at least 
three independent experiments. Luciferase 
values were normalized for cotransfected β-gal 
or GFP and are illustrated as mean fold 
induction. Error bars represent standard 
deviation of the mean.  
Statistical Significance Calculations - 
Differences between samples were analyzed 
using the paired Student’s T-Test. Two-tailed 
probability values of <0.05 and <0.01 were 
considered significant and highly significant, 
respectively. p-values are given within the figure 
legends. 
Cell extracts, Western Blotting & 
Densitometry - For p65 nuclear translocation and 
IκBα degradation, cells were grown and 
transfected in 6cm (HEK 293) or 10cm dishes 
(MEF). 48hrs post transfection cells were 
stimulated with 10ng/ml TNFα (mouse or human 
rTNFα, R&D systems) for the indicated time 
points. Cells were harvested and nuclear 
extracts were prepared as described elsewhere 
(40). For determination of total p65, cells were 
lysed in 1xpassive lysis buffer (Promega). 
Proteins were separated by 10% SDS-PAGE, 
transferred electrophoretically onto a 
nitrocellulose membrane (Hybond-C, Amersham) 
and blocked in 5% non fat dry milk in PBS/0,1% 
Tween-20 for 1h at room temperature before 
incubation with the first antibody over night 
(4C). The following antibodies were used: α-myc 
(sc-40), α-β-actin (sc-1616), α-p65 (sc-109) α-
IκBα (sc-203), and α-SP1 (sc-59), all obtained 
from Santa Cruz Biotechnology, α-GAPDH was 
from Chemicon (MAB 374). The α-TNFα blocking 
antibody (R&D systems, AF-410-NA) was used at 
a concentration of 5µg/ml. The α-TTP antibody 
was kindly provided by P. Kovarik. HRP-
conjugated antibodies α-rabbit IgG, α-mouse 
IgG (Amersham) and α-goat IgG (Santa Cruz) 
were used as secondary reagents. Blots were 
developed using chemiluminescence (West Pico, 
Pierce & ECL Detection Reagents, Amersham). 
Densitometric analysis of nuclear p65 levels was 
done using the background-corrected integrated 
densities  of  the  p65  bands  normalized  to the 
SP-1 bands assessed by the ImageJ software 
freely available at http://rsb.info.nih.gov/ij/. 
Immunocytochemistry - Cells were seeded 
onto fibronectin-coated Lab Tek II Chamber 
Slides (Nunc), transfected with either empty 
vector or mycTTP and 24hrs later stimulated 
with TNFα (20ng/ml) for the indicated times. 
Cells were fixed with 4% paraformaldehyde and 
permeabilized with 0.5% Triton X-100. 
Immunostaining of p65 was done using the 
rabbit-α-p65 antibody (sc-109; Santa Cruz 
Technology; 1:500), mycTTP was detected with 
mouse-α-myc antibody (sc-40, Santa Cruz) 
followed by goat-α-rabbit Alexa 488 (molecular 
probes) and APC goat-α-mouse (BD Biosciences) 
secondary reagents at dilutions of 1:5000 and 
1:500, respectively. For NFAT translocation, cells 
were transfected with GFP-NFATc and mycTTP 
expression vectors as described above and 
stimulated with Ionomycin (500mM final conc.; 
Sigma). 
Real time PCR - Total RNA was isolated from 
either HEK 293 cells or MEF grown in 6-well 
plates using the Roche High Pure RNA Isolation 
Kit, according to the manufacter’s protocol. 1µg 
RNA was reverse transcribed using the TaqMan 
reverse transcription kit (Applied Biosystems) 
with random hexamers and MuLV reverse 
transcriptase following the manufacter’s 
recommendations. Real time PCR was performed 
in a LightCycler (Roche) using SYBR green for 
detection. Experiments were done in triplicates,
the relative amount of mRNA was calculated 
using the Pfaffl method and normalization to β2-
micoglobulin. Error bars represent standard 
deviation of the mean. Primer sequences are 
given in Supplementary Table 1.  
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Fig. 1: TTP attenuates NF-κB activity. HEK 293 cells were transfected with luciferase reporter genes driven by either the IL-8 promoter (A),  
the Tissue Factor promoter (B), or a truncated version of the IL-8 promoter (C) as shown schematically on top (● represents NF-κB ■ represents 
AP-1 and    represents C/EBP transcription factor binding sites). Luciferase activity was analyzed before (control) and after TNFα stimulation 
(10ng/ml, 16hrs) in the absence (EV, empty vector) or presence of coexpressed TTP and normalized to the activity of cotransfected β-
Galactosidase (β-Gal). Mean fold induction was calculated in relation to unstimulated conditions (control).  * P<0.05, ** P<0.01, compared to the 
respective EV sample.
 
Results 
 
 
TTP specifically attenuates NF-κB dependent 
transcription. Our investigations of negative 
feedback regulators and potential contributors to 
the resolution phase of the inflammatory process 
resulted in the observation that TTP has the 
capacity to suppress the transcriptional activity 
of different promoters of inflammatory genes. 
TTP reduced basal as well as TNFα-stimulated 
luciferase expression driven by the human IL-8 
(Fig. 1A) or Tissue Factor (TF) promoter (Fig. 
1B) in HEK 293 cells. These promoters contain 
binding sites for various transcription factors 
including C/EBP, AP-1, SP-1 and NF-κB. In order 
to gain mechanistic insight into which 
transcription factor or signaling pathway was 
affected by TTP, we used a truncated version of 
the IL-8 promoter containing only one NF-κB site 
~100bp upstream of the transcriptional start. 
This modified promoter responded to TTP 
similarly as did the full length promoters (Fig. 
1C), suggesting that the NF-κB site accounted 
for TTP sensitivity. Consequently, we analyzed a 
minimal artificial promoter containing a 
multimerized NF-κB binding site and observed 
that it was also potently inhibited by TTP (Fig. 
2A). These findings could be reproduced in other 
cell types such as HeLa and human umbilical 
vein endothelial cells (HUVEC; data not shown). 
Conversely, the lack of TTP generates conditions 
of a “pre-activated” state in knock out 
fibroblasts, reflected by a ~10 fold higher basal 
NF-κB level in TTP deficient cells (Fig. 2B, left). 
Furthermore, knock-down of endogenous TTP in 
HUVEC by RNA interference enhanced NF-κB 
activity (Fig. 2B, right) recapitulating the 
situation observed in TTP k.o MEF. Similar 
results were obtained in HEK 293 cells (Sup. Fig. 
1A). The functionality of the siRNA was verified 
on the mRNA (Fig. 2C) and protein level (Sup. 
Fig. 1A, bottom panels). In addition, 
reconstitution of TTP expression by transient 
transfection into TTP k.o cells resulted in a 
5xNF-κB activity that was comparable to that 
observed in WT cells (Sup. Fig. 1B). Importantly, 
TTP did not decrease the basal and induced 
transcriptional activity of either minimal SP-1 or 
p53 or NFAT dependent promoters, as shown in 
Fig. 2D, demonstrating specificity and ruling out 
possible effects on the reporter plasmids. 
Additionally, we did not observe any influence of 
TTP on the degradation of luciferase mRNA 
(Sup. Fig. 1C). Together, this demonstrates that 
TTP specifically interferes with transcriptional 
activation triggered by the transcription factor 
NF-κB. 
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Fig. 2: Specificity towards NF-κB activity. A) HEK 293 cells were transfected with a luciferase reporter gene driven by a minimal NF-κB 
promoter containing 5 NF-κB binding sites (5xNF-κB-luc; scheme on top) and luciferase activity was analyzed as described in Fig. 1. ** 
P<0.01, compared to the respective EV samples. B) Lack of TTP triggers NF-κB activity. Left: 5xNF-κB promoter activity was analyzed in wild 
type (wt) versus TTP knock out (k.o) MEF. Luciferase levels were normalized to cotransfected β-Gal. Right: human umbilical vein endothelial 
cells (HUVEC) were transfected with the 5xNF-κB-luc reporter along with a siRNA directed against TTP (siTTP) or a scrambled control (Scr) 
and luciferase activity normalized to coexpressed GFP was assessed 48hrs post transfection. ** P<0.01, compared to wt (left) or the 
scrambled control (right). C) Real time PCR analysis of TTP mRNA levels normalized to β2-microglobulin in HUVEC 48hrs post transfection with 
either siTTP or the scrambled control (Scr) used in (B). A representative experiment is shown. D) TTP does not bias NF-κB independent 
promoters. HEK 293 cells were transfected with either a SP-1 (left), a p53 (middle) or a NFAT promoter-dependent (right) luciferase reporter 
gene in the presence (TTP) or absence of TTP (EV). Luciferase activities were analyzed in the absence (control) or presence of cotransfected 
SP-1, p53, or NFAT expression plasmids, respectively. * P<0.05, ** P<0.01, compared to the respective EV samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TTP interferes with NF-κB signaling 
downstream of the IKK signalosome, at the level 
of p65.  Based on the results above we sought 
to examine whether TTP interferes with NF-κB 
signaling up- or downstream of the IKK 
signalosome. Activation of NF-κB by TRAF2 or 
TAK1/TAB1, acting upstream of the IKK 
complex, did not result in the abrogation of TTP 
mediated NF-κB inhibition (Fig. 3A). Moreover, 
TTP also potently inhibited IKK2- and even NF-
κB/p65-mediated activation of the 5xNF-κB 
reporter in HEK 293 cells (Fig. 3B), suggesting it 
acts downstream or at the level of p65. In 
addition, overexpression of p65 did not impede 
TTP action in WT nor in reconstituted k.o MEF 
(Sup. Fig. 2A). Further examination of TTP 
effects on p65 induced IL-8 promoter activity 
(Sup. Fig. 2B) confirmed the results obtained for 
the artificial NF-κB promoter. Increasing 
amounts of p65 expression levels could not 
overcome the TTP-mediated inhibition (Fig. 3C) 
and in addition, attenuation of NF-κB activity 
occurred in a dose dependent manner (Fig. 3D). 
We  observed  50%   inhibition  of p65-mediated 
luciferase activity at approximately 7ng 
cotransfected TTP. Since overexpression of p65 
might bypass its natural regulation through the 
IκBs, we examined a possible influence of TTP 
on IκBα degradation. We found that TTP did not 
prevent TNFα induced IκBα degradation, neither 
in HEK 293 cells after overexpression (Fig. 3E, 
top), nor was it altered in TTP k.o compared 
with WT MEF (Fig. 3E, bottom). 
Another important step prior to 
transcriptional activation by NF-κB is the 
recruitment of nuclear coactivators such as 
CBP/p300, or activating kinases like MSK1, into 
the transcriptional activation complex. Analysis 
of these nuclear signaling components in 
transient transfection experiments, using the 
respective expression vectors, revealed that 
neither of them could dampen the inhibitory TTP 
effect (Fig. 3F). To exclude that TTP affects p65 
mRNA or protein, we analyzed these levels in 
HEK 293 cells after TTP overexpression (Sup. 
Fig. 2C, left) and in TTP k.o MEF (Sup. Fig. 2C, 
right) and could not detect significant 
differences. 
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Fig. 3: TTP interferes with NF-κB signaling downstream of p65 transactivation. HEK 293 cells were transfected with 5xNF-κB-luc 
alone (control) or in combination with TAB1/TAK1, TRAF2 (A), p65 or IKK2 expression plasmids (B) and luciferase activities were analyzed in 
the absence (EV) or presence of coexpressed TTP. Mean fold induction was calculated in relation to basal 5xNF-κB activity (control). ** 
P<0.01, compared to the respective EV samples. C) Increased p65 levels do not compensate for the inhibition of NF-κB by TTP. HEK 293 cells 
were transfected with 5xNF-κB-luc either in the absence (EV) and presence of TTP (TTP) (** P<0.01, compared to the EV sample) or together 
with increasing amounts of p65 (0.1-0.4µg) and a constant amount of TTP (100ng) expression plasmids, as indicated. (** P<0.01, compared 
to the p65 induced sample). 5xNF-κB promoter activity was analyzed as above. Protein levels of p65 as well as myc-tagged TTP were 
assessed by Western Blotting, β-actin represents the loading control (middle panels). D) TTP reduces NF-κB activity in a dose-dependent 
manner.  HEK 293 cells were transfected with increasing amounts of TTP as indicated (1-100ng) in combination with a constant amount 
(0.1µg) of p65 and 5xNF-κB activity was determined as described above. ** P<0.01, compared to the sample without TTP coexpression. E) 
IκBα degradation is not affected by TTP. Top: HEK 293 cells were transfected with either empty vector (EV) or myc-tagged TTP and 
stimulated with TNFα (10ng/ml) for the indicated time points followed by preparation of cytoplasmic extracts. IκBα degradation (upper panel) 
as well as ectopic TTP expression (middle panel) was assessed by Western Blotting. β-actin was used as loading control (lower panel). 
Bottom: Wild type (wt) and knock out (k.o) MEF were stimulated with TNFα (10ng/ml) for 15 minutes and cytoplasmic extracts were 
subjected to Western Blot analysis for IκBα degradation. β-actin served as loading control (lower panel). F) Nuclear p65-coactivators can not 
counteract TTP.  HEK 293 cells were transfected with a 5xNF-κB reporter in combination with p65 (EV+p65), along with CBP, p300 or MSK1 
expression vectors. Luciferase activities were analyzed in the presence (TTP) and absence of coexpressed TTP. Fold induction was calculated 
in relation to the basal reporter activity (not displayed). ** P<0.01, compared to the respective p65-induced EV samples. 
 
 
 
 
 
 
 
 
 
 
 
 
The mRNA binding ability of TTP is 
dispensable for its inhibitory effect on NF-κB 
promoter activity.  One simple explanation of 
our results could have been that TTP affects the 
stability of an ARE-containing mRNA that 
encodes a protein necessary for full NF-κB 
activation. Therefore we took advantage of the 
TTP mutant C124R (Fig. 4A), which is deficient 
in ARE binding and therefore cannot destabilize 
e.g. TNFα mRNA ((41-43) and Sup. Fig. 3A). 
TTP-C124R retained the capacity to inhibit 5xNF-
κB activity, both after stimulation with 
cotransfected  p65   (Fig. 4B),  as well as  under  
 
basal    conditions   (Fig. 4C).  In   contrast,  the 
TTP construct comprising the zinc-finger domain 
only (TZF; Fig. 4A), which binds mRNAs 
efficiently (44) but fails to induce degradation 
(Sup. Fig. 3A), displayed no influence on 
luciferase activity (Fig. 4C).  
This suggests that the ability of TTP to inhibit 
NF-κB is independent of its mRNA binding 
capacity, but requires the presence of the N- 
and/or C-terminal domains. As already observed 
for TTP (Fig. 2D), the C124R mutant did not 
affect SP-1- or p53-dependent promoter 
activities (Sup. Fig. 3B). 
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Fig. 4: Attenuation of NF-κB activity is independent of the mRNA binding ability of TTP. A) Schematic depiction of TTP constructs 
used in reporter gene assays. Numbers represent amino acid residues of human TTP. A single amino acid mutation within the first zinc-finger 
(C124R) completely abolishes RNA binding. TZF: tandem zing-finger. CCCH: cysteine-cysteine-cysteine-histidine zinc-finger structure; all 
proteins are N terminally linked to a myc-tag. B) HEK 293 cells were transfected with 5xNF-κB-luc alone (EV) or in combination with a p65 
expression vector as indicated. The effect of coexpression of either TTP or the RNA binding mutant C124R on p65 stimulated 5xNF-κB 
promoter activity was monitored by analysis of luciferase expression levels as described above. Mean fold induction was calculated in relation 
to the empty vector sample. The bottom panel represents Western analysis of the same cell lysates and shows equal protein expression levels 
of both TTP and C124R by detection with a α-myc antibody. ** P<0.01, compared to the p65-induced sample. C) HEK 293 cells were 
transfected with 5xNF-κB-luc alone (EV) or in combination with increasing amounts of TTP-C124R or TTP-TZF expression plasmids. Luciferase 
activities were analyzed, and cell lysates subjected to Western Blotting (bottom panel) to verify expression of TTP constructs as described in 
(B). Numbers at the left side represent molecular weight in kDa. * P<0.05, compared to the EV sample.   
 
 
 
 
 
 
 
 
 
Fig. 5: The p65 region containing the NLS/NES motifs accounts for TTP sensitivity. A) Schematic representation of expression 
constructs containing different p65 domains fused to the yeast Gal4 DNA binding domain (Gal4DBD: Gal4 DNA binding domain; NLS: nuclear 
localization signal; NES: nuclear export signal; TA1 & TA2: transactivation domain 1 & 2; for detailed description see Experimental Procedures 
and (35). B) HEK 293 cells were transfected with the yeast based Gal4 reporter plasmid pFR-luc (control) together with p65° (see scheme (A)) 
to enable promoter activity, and the effect of TTP coexpression on p65° induced luciferase expression was analyzed (p65°/TTP). The impact 
of TTP coexpression on promoter activity induced by the p65 mutants M1-M3 (see scheme (A)) is depicted in (C). * P<0.05 compared to the 
respective EV sample, ** P<0.01, compared to the p65° induced sample. 
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sample. Relative p65 levels are shown in relation to time point 0. 
Numbers on the top of the bars represent the percental 
reduction of nuclear p65 levels in the presence of TTP. B) Top: 
TTP k.o MEF exhibit increased nuclear p65 levels. Cytoplasmic 
(Cyt) and nuclear (Nuc) extracts prepared from wild type (WT) 
and TTP k.o MEF were analyzed by Western Blotting (upper 
panels) for p65 levels in the presence of an α-TNFα antibody. 
SP-1 is shown as loading control and for the purity of the nuclear 
fraction. Bottom: Densitometric analysis of nuclear p65 levels 
based on the Western Blot on top. Analysis was done as 
described in (A). C) Immunocytochemical analysis showing TTP 
influence on p65 nuclear translocation in human umbilical vein 
endothelial cells (HUVEC). Cells were transfected with a TTP 
expression plasmid (mycTTP), stimulated with TNFα (20ng/ml) 
for 15 minutes and endogenous p65 (green, left panels) as well 
as ectopically expressed TTP (red, right panels) were detected 
by immunocytochemistry. TTP-transfected cells are indicated by 
an arrow.   
TTP impairs cytoplasmic-nuclear transition of 
p65.  Having established that TTP inhibits NF-κB 
downstream or at the level of p65 we sought to 
gain further insight into its mode of action. Since 
one of the additional regulatory steps of NF-κB 
activation occurs at the level of transactivation, 
we utilized different hybrid constructs where 
parts of p65 are fused to the yeast Gal4 DNA 
binding domain (Fig. 5A). When we tested the 
ability of these constructs to influence Gal4 
dependent luciferase expression we found that 
the exchange of the N-terminal Rel homology 
domain with the yeast Gal4 DNA binding domain 
(DBD) retained the inhibitory effect of TTP (Fig. 
5B), indicating that neither p65 dimerization nor 
DNA binding was impaired. Further truncations 
of the p65 protein revealed that TTP could not 
suppress the activity of each of the two 
transactivation domains when they were fused 
directly to the Gal4 DBD. The only region of p65 
that was sensitive to TTP was the central part, 
which contains the NLS as well as the nuclear 
export sequence (NES), suggesting that TTP 
may prevent import or expedite export of the 
transcription factor (Fig. 5C). Comparable results 
were obtained in HeLa cells (data not shown).  
To substantiate these data, we investigated the 
possible influence of TTP on p65 subcellular 
localization. Therefore we analyzed p65 protein 
levels in cytoplasmic and nuclear fractions of 
TNFα induced HEK 293 cells and found that the 
overexpression of TTP impaired nuclear 
accumulation of p65 (Fig. 6A, top). Additionally, 
and in line with previous reporter results (Fig. 
2B, left; Sup. Fig. 1B), the nuclear localization of 
p65 was enhanced in TTP k.o MEF (Fig. 6B, top) 
supporting the notion of a “pre-stimulated” 
scenario. Although these cells do not express 
detectable amounts of TNFα ((43) and real-time 
PCR data not shown) we wanted to rule out that 
potential minute amounts of TNFα are the cause 
for enhanced NF-κB activity in k.o cells. 
Therefore, we performed this experiment in the 
presence of a neutralizing α-TNFα antibody. 
Furthermore, immunocytochemical analysis of 
HUVEC, transiently transfected with TTP, 
showed reduced translocation of endogenous 
p65 after TNFα stimulation (Fig. 6C; Sup. Fig. 
4A); in contrast, shuttling of NFAT was not 
affected (Sup. Fig. 4B). 
 
Fig. 6: TTP impairs p65 
cytoplasmic-nuclear shuttling. A) 
Top: Western Blot analysis of 
endogenous p65 and myc-tagged TTP 
in cytoplasmic and nuclear extracts 
prepared from HEK 293 cells 
stimulated with TNFα for the indicated 
time points, 48hrs after transfection 
with empty vector (EV) or TTP 
(mycTTP expression plasmid); LC*: 
loading control, β-actin was used for 
the cytoplasmic and SP-1 for the 
nuclear fraction. Bottom: 
Densitometric analysis of nuclear p65 
levels based on the Western Blot 
shown in the upper panel using the 
ImageJ software (for detailed 
information see Experimental 
Procedures). p65 levels were 
normalized  to  SP1  levels in the same  
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see Experimental Procedures).B & C) HEK 293 cells were transfected with 5xNF-κB-luc alone (control) or in combination with either wt p65 
(wt), SV40NLSp65 (SV40NLS) and SV40NLSΔNESp65 (ΔNES) (B) or wt p65 (wt) and p53NLSΔNLSp65 (p53NLS) (C). Luciferase activities were 
analyzed in the absence (EV) or presence of coexpressed TTP. Fold induction was calculated in relation to the basal reporter activity (control). 
* P<0.05, ** P<0.01, compared to the respective EV samples. 
TTP impairs p65 nuclear import and affects 
the transcriptional onset of specific NF-kB target 
genes in an ARE independent manner. NF-
κB/p65 was shown to constitutively shuttle 
between cytoplasm and nucleus under basal 
conditions (45). The abundance of regulatory 
proteins like IκBα, in addition to the appropriate 
composition of the nuclear pore complex, as well 
as the accessibility of NLS and NES, are 
indispensable for the proper timing of import 
and export. The NLS of p65 belongs to the 
monopartite class of leader-motifs (46,47) that 
further includes those of the SV40 T antigen and 
the human c-Myc.  Recently it was described by 
Li and colleagues (48) that the transcription 
factor p53 shuttles through a specific nuclear 
import pathway that seems to be selective for 
the bipartite p53-NLS and different from the 
pathway used by the monopartite SV40 T 
antigen. Accordingly, we tested different p65-
NLS/NES mutants, as summarized schematically 
in Fig. 7A, in reporter gene assays. The N-
terminal fusion of the SV40NLS (PKKKRKV) to 
wild type p65 resulted in activation of 5xNF-κB 
activity similar in strength as the induction 
achieved with the WT protein, and in both cases 
TTP had a comparable inhibitory effect (Fig. 7B). 
In contrast, the fusion of the bipartite nuclear 
leader of p53 (see scheme Fig. 7A), that is 
distinguished from the  monopartite class of p65 
and SV40 nuclear localization signals, 
significantly abrogated the inhibitory effect of 
TTP (Fig. 7C). Mutation of the nuclear export 
signal of p65 (ΔNES) resulted in strongly 
enhanced promoter activity, but could 
nevertheless be suppressed by TTP (Fig. 7B). 
This suggests that TTP does not act via 
enhancing p65 export, but through regulation of 
nuclear import that is dependent on the nature 
of the p65 NLS. To study the biological 
consequences of altered NF-κB activity, we 
analyzed the levels of NF-κB dependent target 
genes in WT and TTP k.o MEF. To exclude any 
contribution of AMD, NF-κB target genes were 
selected with regard to the absence of any ARE 
in their respective mRNAs (adapted from 
http://people.bu.edu/gilmore/nfkb/ 
target/index.html). Six NF-κB dependent genes, 
belonging to diverse groups of NF-κB targets 
were chosen (Table 1) and the absence of any 
AU-cluster was confirmed bioinformatically. They 
were analyzed by real time PCR for their relative 
expression levels in WT compared to TTP 
deficient MEF (Fig. 8). While MCP-1, also known 
as the macrophage chemotactic protein, as well 
as the antioxidant genes FTH1 and TXN2 were 
unaffected (Fig. 8, left graph), the chemokine 
RANTES as well as Gadd45β and TRAF1 were 
substantially upregulated in TTP k.o cells (Fig. 8, 
right graph). 
 
Fig. 7: TTP affects p65 nuclear 
import. A) Schematic representation of 
p65 expression constructs used for 
reporter gene assays in (B) and (C). WT 
p65: wild type p65; SV40NLS p65: the 
monopartite SV40 nuclear localization 
signal (PKKKRKV) fused to the N-
terminus of wild type p65; 
SV40NLSΔNES p65: mutation of the 
nuclear export sequence within the 
SV40NLSp65 construct; p53NLSΔNLS 
p65: the p53 bipartite nuclear 
localization signal 
(KRALPNNTSSSPQPKKKP) fused to the 
N-terminus of wild type p65, the 
internal WT p65 NLS KRKR mutated to 
AAAR. (for detailed cloning information
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Table 1 
Bioinformatic analysis of selected NF-κB target genes. NF-κB dependent target genes, involved in a variety of different cellular 
functions, were preselected from http://people.bu.edu/gilmore/nf-kb/target/index.html and analyzed for the absence of an AU-rich element 
(ARE) in the 3’-UTR of the respective mRNAs using the ARED database at http://brp.kfshrc.edu.sa/ARED/. Targets lacking an ARE-motif were 
further analyzed for the presence/absence of the minimal AU-pentamer AUUUA. 
* mus musculus RefSeq; **ARED: AU-rich element database; the ARED organism search engine was used for preanalysis; *** AUUUA: 
minimal pentamer, core sequence of classI/II/III ARE clusters. 
 
 
 
 
 
 
 
Fig. 8: TTP controls the expression of ARE-less NF-κB target genes. Real time PCR analysis of selected, ARE-less NF-κB dependent 
genes (Table 1) in wt and TTP k.o MEF. Relative expression levels were normalized to β2-microglobulin, the results shown are representatives 
of two independent experiments done in triplicates. ** P<0.01, compared to the respective wt samples. 
 
 
 
 
 
 
 
 
Discussion 
 
The notion that the zinc-finger protein 
Tristetraprolin might act as a negative regulator 
of transcription initially emerged more than 10 
years ago, when the first suppressive effects on 
promoters were described (11). Nevertheless, 
this view  has taken a  back seat by the 
concomitant  finding  that  TTP  acts  as   mRNA 
destabilizing protein. However, evidence has 
accumulated that TTP might have a broader 
function. Examples include the influence on 
other RNA binding proteins, e.g. the KH-type 
splicing regulatory protein (KSRP) (49), as well 
as the proposed multifunctional activity in the  
control of glucocorticoid mediated gene 
expression  (50).  We describe here   that    TTP 
is    involved   in   the   negative   transcriptional   
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regulation of promoters containing NF-κB 
binding sites in different cell types. TTP inhibits 
the induced activity of these promoters about 
70-95% while the influence on the basal levels 
fluctuates below 50%. This can be explained by 
the fact that NF-κB constitutively shuttles 
between cytoplasm and nucleus (45) leading to 
a basal promoter activity with its magnitude 
being determined by the actual situation and 
condition of the cell. The negative regulatory 
role of TTP was further supported by the 
analysis of TTP deficient mouse embryonic 
fibroblasts as well as by siRNA mediated knock 
down of endogenous TTP in HUVEC.  
TTP exhibited a dose dependent effect on 
NF-κB with only ~7ng of transfected TTP 
expression plasmid resulting in half-maximal 
reduction of promoter activity, an amount that 
was below our detection limit on Western Blots 
(whereas endogenous TTP could be detected at 
least after stimulation in other cell types; data 
not shown). This indicates that the transfected 
amounts are well below the induced, 
endogenous TTP levels of other cell types. Lai 
and colleagues have shown previously (14) that 
the overexpression of human TTP exhibits 
different effects on the degradation of TNFα 
mRNA dependent on the expression levels: while 
low levels of TTP efficiently destabilize the TNFα 
message, they observed that higher levels lead 
to the stabilization of the mRNA, which is 
explained by the possibility that TTP might form 
inactive dimers at higher concentrations or 
sequester components of the RNA degradation 
machinery. We initially hypothesized that TTP 
might trigger the down-regulation of the 
expression of one ore more components of the 
NF-κB signaling pathway through its known 
mRNA destabilizing activity. However, the use of 
TTP constructs, which either carry a mutation in 
the zinc-finger domain (C124R) that impairs ARE 
binding and mRNA degradation, or lack the N-
and C-terminal domains (TZF), provided 
evidence that TTP inhibits NF-κB independent of 
its well-described mRNA destabilizing function. 
The fact that the RNA binding mutant C124R 
could not diminish, but rather augment TNFα 
mRNA levels has already been observed by Lai 
and colleagues and was confirmed in our 
experiments (Sup. Fig. 3A). It can be explained 
by the inhibition of mRNA turnover due to 
dominant-negative function of this mutant (41). 
Further  examination of  the  mechanism  of  
TTP  action  unveiled  that   TTP  influences  the 
activation of NF-κB at the level of p65: no 
upstream mediator of NF-κB signaling (TRAF2, 
TAK1/TAB1, IKK2)  could  overcome  the strong, 
inhibitory TTP effect, IκBα degradation was not 
affected and overexpression of the known p65 
nuclear co-activators CBP, p300 and MSK1 did 
not prohibit TTP action. Besides, neither total 
p65 protein amounts nor mRNA levels were 
influenced and no physical interaction of TTP 
with p65 could be demonstrated by 
coimmunoprecipitation (data not shown). 
However, the results of follow-up experiments 
revealed that the nuclear import of NF-κB/p65 
was affected by TTP: biochemical analysis 
demonstrated that p65 appeared in the nucleus 
15 minutes post TNFα stimulation in control 
cells, whereas TTP transfected cells showed a 
severely impaired nuclear translocation. 
Densitometric analysis of nuclear p65 levels 
revealed that already under unstimulated 
conditions less p65 was present in the nucleus 
and the difference became even more evident 
after stimulation with TNFα, in agreement with 
the results obtained by the reporter gene 
assays. These findings were further confirmed at 
the single-cell level by immunofluorescent 
analysis of endogenous p65 in primary HUVEC. 
In line with the promoter studies performed in 
TTP k.o MEF, we found that p65 exhibited 
increased nuclear localization under 
unstimulated conditions in these cells. Here, the 
lack of TTP seems to allow enhanced nuclear 
shuttling of NF-κB, leading to a “pre-stimulated” 
situation that is reflected by the upregulation of 
certain NF-κB target genes. It has to be pointed 
out that the target genes analyzed in untreated 
TTP k.o cells provide an insight into the 
prestimulated situation generated by TTP 
deficiency. It is in all probability that under e.g. 
TNFα stimulated conditions other and/or 
additional target genes might be differentially 
regulated. The fact that only a subset of NF-κB 
regulated genes is affected in our experiments 
can be explained by the complexity of NF-κB 
activation: the selective transcriptional onset of 
specifically required target genes is dependent 
on the formation of distinct NF-κB 
dimer/heterodimer combinations, the abundance 
and distribution of essential cofactors as well as 
the epigenetic regulation of the accessibility of 
the promoters. The proper timing and interplay 
of these components may facilitate the 
differential expression of a plethora of NF-κB 
dependent genes.   Our analysis revealed the 
ARE-less NF-κB targets RANTES, Gadd45β and 
TRAF1 being upregulated in TTP k.o MEF. 
RANTES is a chemokine that appears 
chemotactic for T cells, eosinophils, and 
basophils, and plays an active role in recruiting 
leukocytes  into  inflammatory sites.   TRAF1 is a 
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associated death domain; FCS, fetal calf serum; GFP, green fluorescent protein; GM-CSF, 
granulocyte macrophage colony stimulating factor; HRP, horseradish peroxidase; Ier3: Immediate 
early response 3; IκBα, inhibitor of kappa B alpha; MHC, major histocompatibility complex; MuLV, 
murine leukemia virus; MSK-1, mitogen- and stress-activated protein kinase 1; NFAT, nuclear factor 
of activated T cells; PBS, phosphate buffered saline; RIP, receptor interacting protein; TAB, 
transforming growth factor activated protein kinase 1 binding protein; TAK1, transforming growth 
factor beta activated kinase 1; TNFα, tumor necrosis factor alpha; TRADD, TNF receptor-associated 
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3.2.1. Supplemental Material 
 
 
Supplementary Fig. 1: 
 
A) HEK 293 cells were transfected with 5xNF-κB-luc alone (EV) or in combination with TTP, along with a siRNA directed against TTP (siTTP) or 
a scrambled control (Scr). Luciferase activity was assessed 48hrs post transfection and normalized to coexpressed βGal. Mean fold induction 
was calculated in respect to the basal promoter activity (control). Knock-down efficiency of ectopically expressed TTP was confirmed by 
Western Blotting (lower panel) β-actin was used as loading control. B) 5xNF-κB promoter activity was analyzed in wild type (wt) versus TTP 
knock out (k.o) MEF before (EV) and after reconstitution of TTP expression. Luciferase levels were normalized to cotransfected β-Gal. * 
P<0.05, ** P<0.01, compared to the respective EV samples. C) TTP does not impact luciferase mRNA degradation. HEK 293 cells were 
transfected with 5xNF-κB-luc alone (EV) or in combination with a TTP expression vector (TTP). Cells were treated with ActinomycinD (5µg/ml) 
as indicated, and the degradation of luciferase mRNA was analyzed by real-time PCR as described in Experimental Procedures. Values 
obtained for the untreated samples were set to 10 and the experiment was done in triplicates. Error bars represent standard deviation of the 
mean. 
 
 
 
 
Supplementary Fig. 2: 
 
 
 
A) Lack of TTP mimics “pre-stimulation”.  5xNF-κB promoter 
activity was analyzed in wild type (wt) versus TTP knock out 
(k.o) MEF before (control) and after stimulation with p65 
(p65) as well as in the presence of cotransfected TTP 
(p65+TTP). Luciferase levels were normalized to 
cotransfected β-Gal. * P<0.05 compared to the respective 
p65 induced sample. B) TTP dampens p65 induced IL-8 
promoter activity. HEK 293 cells were transfected with a 
reporter gene construct driven by the IL-8 promoter (scheme 
as described in Fig. 1) alone (control) or stimulated by a 
cotransfected p65 expression plasmid. Luciferase expression 
levels were assessed in the presence (TTP) and absence (EV) 
of coexpressed TTP and normalized to the activity of 
cotransfected β-Gal. Mean fold induction was calculated in 
relation to unstimulated conditions (control).  * P<0.05, ** 
P<0.01, compared to the respective EV samples. C) Total p65 
expression levels are not influenced by TTP. Left: Endogenous 
p65 mRNA levels assessed by real time PCR (upper graph) or 
Western Blot analysis (lower panel) in control (EV) or TTP 
transfected (TTP) HEK 293 cells. Relative mRNA levels were 
normalized to β2-microglobulin and expression of ectopic TTP 
as well as equal protein loading was confirmed by α-myc 
(TTP) and GAPDH antibodies, respectively. Right: Expression 
levels of endogenous p65 in wild type (wt) and TTP k.o MEF 
determined by real time PCR (top) and Western Blot analysis 
(bottom). β-actin represents the loading control. Results are 
representatives of three independent experiments done in 
triplicates. 
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Supplementary Fig. 3: 
 
 
A) TTP-C124R does not initiate degradation of TNFα mRNA. HEK 293 cells were transfected with either empty vector (EV), myc-tagged TTP 
(TTP), TZF (TZF) or the RNA-binding mutant C124R (C124R) (see scheme Fig. 4) and relative TNFα mRNA levels were determined by real 
time PCR 24hrs post transfection. Expression levels were normalized to β2-microglobulin and PCR samples were subjected to a control 2% 
agarose gel (top insert). B) TTP-C124R does not affect SP-1 and p53 dependent promoters. HEK 293 cells were transfected with either a SP-1 
(left) or a p53 (right) promoter dependent luciferase reporter plasmid. The influence of cotransfected TTP or C124R was analyzed under 
unstimulated conditions (control) as well as after activation with cotransfected SP-1 and p53 expression plasmids, respectively. * P<0.05 
compared to the respective EV samples. 
 
 
 
 
Supplementary Fig. 4: 
 
TTP impairs p65 but not NFAT nuclear translocation. A) Human umbilical vein endothelial cells (HUVEC) were transfected with a TTP 
expression vector (mycTTP), stimulated with TNFα (10ng/ml) for 15 minutes and endogenous p65 (green, left panels) and ectopically 
expressed TTP (red, right panels) were detected by immunocytochemistry. TTP-transfected cells are indicated by an arrow. B) HUVEC were 
transfected with expression vectors for TTP (mycTTP) and a NFAT-GFP fusion construct (GFP-NFATc), and nuclear translocation of NFAT was 
analyzed after stimulation with Ionomycin (500nM) for 10 minutes. (NFAT: green; TTP: red). 
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Supplementary Table 1: 
 
Application Sequence 5’-3’ 
RNA interference  
Zfp36_1* ACA AGA CUG AGC UAU GUC GGA CCU U 
Zfp36_2* UGG AUC UGA CUG CCA UCU ACG AGA G 
Zfp36_3* CCU GGG AUC CGA CCC UGA UGA AUA U 
scrambled control ACA AGA GUG UGC AAU CUC GGA GCU U 
Real time PCR  
human p65 fwd CTA CGA CCT GAA TGC TGT GC 
human p65 rev GCC AGA GTT TCG GTT CAC TC 
mouse p65 fwd GAG CCC ATG GAG TTC CAG TA 
mouse p65 rev CAA AGT TGA TGG TGC TGA GG 
human b2mg fwd GAT GAG TAT GCC TGC CGT GTG 
human b2mg rev CAA TCC AAA TGC GGC ATC T 
mouse b2mg fwd ATT CAC CCC CAC TGA GAC TG 
mouse b2mg rev TGC TAT TTC TTT CTG CGT GC 
human TTP fwd GGA TCT GAC TGC CAT CTA CGA 
human TTP rev CGG GAG GTG ACC CCA GAC 
human TNFα fwd CCC CAG GGA CCT CTC TCT AA 
human TNFα rev GCT TGA GGG TTT GCT ACA ACA 
mouse MCP-1 fwd AGG TCC CTG TCA TGC TTC TG 
mouse MCP-1 rev TCT GGA CCC ATT CCT TCT TG 
mouse Fth1 fwd CCT GCA GGA TAT AAA GAA ACC A 
mouse Fth1 rev GAA GTC ACA TAA GTG GGG ATC A 
mouse Txn2 fwd TGG ACT TTC ATG CAC AGT GG 
mouse Txn2 rev GGC ACA GCT GAC ACC TCA TA 
mouse RANTES fwd GTG CCC ACG TCA AGG AGT AT 
mouse RANTES rev GGG AAG CGT ATA CAG GGT CA 
mouse Gadd45β fwd CCT GGC CAT AGA CGA AGA AG 
mouse Gadd45β rev TGA CAG TTC GTG ACC AGG AG 
mouse TRAF1 fwd CCT GAG AGA TGA TGA GGA TCG 
mouse TRAF1 rev GCT CCC CTT GAA GGA ACA G 
TTP subcloning  
TTP fwd CGG AAT TCC CAT GGA TCT GAC 
TTP rev CGG TCG ACT CAC TCA GAA ACA G 
p53NLS cloning  
p53NLS sense AGC TTC CAC CAT GAA GCG AGC ACT GCC CAA CAA CAC CAG 
CTC CTC TCC CCA GCC AAA GAA GAA ACC AGC 
p53NLS antisense 
 
CAT GGC TGG TTT CTT CTT TGG CTG GGG AGA GGA GCT GGT 
GTT GTT GGG CAG TGC TCG CTT CAT GGT GGA 
p53NLS fwd CCA ACA ACA CCA GCT CCT CT 
p53NLSp65 rev GCT GCT CAA TGA TCT CCA CA 
 
 
* pool of 3 oligos 
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3.3. TTP as dual-functional balancer between NF-κB and MAPK signaling 
 
TTP is described as hyperphosphorylated protein in both murine and human cells. TTP phosphorylation 
has been studied by several laboratories, and mass spectrometry as well as site directed mutagenesis 
have identified a number of potential phosphorylation sites and predicted kinases. However, the most 
extensively studied kinase that was shown to phosphorylate and inactivate TTP’s mRNA binding and 
degrading ability remains the MAPK p38α whereas the function of other predicted kinases is still a matter 
of research. 
In respect to these observations we decided to examine whether any of these predicted kinases can 
rescue the effect of TTP mediated downregulation of NF-κB. We tested IKK1, PKA, PKCα, PKCβ, PKCγ and 
PKCζ in NF-κB-dependent reporter gene assays and could not detect any significant differences in respect 
to inhibition of TTP function (data not shown). Strikingly, and although not predicted as a possible kinase 
yet, we found that the MAP3K MEKK1 was able to prevent TTP action whereas the p38α- as well as the 
MEKK1-p38α-induced  NF-κB activity  was effectively  downregulated by TTP  (Fig. 12T, A).  Interestingly,  
 
 
 
 
 
Fig. 12T: MEKK1 counteracts 
TTP inhibitory function. HEK 
293 cells were transfected with 
5xNF-κB-luc alone (control) or in 
combination with either p38α 
and/or MEKK1 (kinase domain 
only) (A), or with p65 and/or 
MEKK1 (kinase domain only) (B, 
left) and luciferase activities were 
analyzed in the absence (EV) or 
presence of coexpressed TTP. B, 
right) HEK 293 cells were 
transfected   with IL-8-luc reporter 
(control) together  with either  p65
and/or MEKK1 (kinase domain only) expression plasmids and luciferase levels were analyzed as 
described above. *, p<0.05 compared with the respective empty vector (EV) samples. C, top) HEK 
293 cells were transfected with 5xNF-κB-luc alone (control) or in combination with either p65, p65 
and TTP or p65, TTP and p38α expression plasmids. Luciferase activities were analyzed in the 
absence (EV) or presence of MEK3. **, p<0.01 compared to the p65 induced sample; ***, 
p<0.001, compared to the p65/MEK3 induced sample. Protein levels of p65, myc-tagged TTP as 
well as the phosphorylation status of p38α were assessed by Western Blotting. β-actin represents 
the loading control (C, bottom). D) HEK 293 cells were transfected with a TTP expression plasmid 
together with either empty vector (EV), p38α, MEKK1 (kd, kinase domain; long and short exposure) 
or MEKK1 and p38α expression plasmids in combination. Whole cell lysates were analyzed for TTP 
expression and “patterning” by application on a 5-12% SDS-gradient gel and Western Blotting.  
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MEKK1 also prohibited the negative effect of TTP on the artificial 5xNF-κB as well as the IL-8 promoter 
when induced with p65 (Fig. 12T, B), whereas co-expression of p38α as well as the additional 
coexpression of the p38α upstream kinase MEK3 did not result in any changes (Fig. 12T, C). Based on 
this result and the fact that p38α mediated TTP phosphorylation results in a well described electrophoretic 
shift of the protein we analyzed the “molecular patterning” of TTP after coexpression with either p38α or 
MEKK1 or both by Western Blotting. As shown by the Blot in Fig. 12T (D) p38α mediated phosphorylation 
of TTP led to a different molecular shift as compared to the modification obtained by coexpression of 
MEKK1. Interestingly, the combined overexpression of MEKK1 and p38α led to a molecular appearance of 
TTP comparable to that of the empty vector (EV) control (Fig. 12T, D, left panel).  
MEKK1 is a 195kDa protein containing a C-terminal kinase domain that facilitates the phosphorylation of 
several different MEKs, with the strongest activity towards MKK4, the upstream kinase for JNKs. Its N-
terminal domain contains a plant homeodomain (PHD) that has a RING finger like structure and exhibits 
E3 Ubiquitin Ligase activity.  
To substantiate our findings and gain further insight into MEKK1 mediated TTP inhibition, we analyzed the 
effect of coexpression of full length MEKK1 compared to its kinase domain only on TTP mediated NF-κB 
inhibition. We observed that while the kinase domain effectively prohibited TTP function, full length 
MEKK1 exhibited a weaker effect (Fig. 13T, A). Moreover, coexpression of a MEKK1-kinase-deficient 
construct (D1369A) led to the complete reconstitution of the TTP-mediated NF-κB inhibition, and mutation 
of  the  PHD domain  slightly  attenuated TTP activity (Fig. 13T, B). In order to exclude the possibility that  
 
 
 
 
 
 
 
Fig. 13T: Kinase domain of MEKK1 accounts for TTP blockage. A) HEK 293 cells were transfected with 5xNF-κB-luc alone (control) or in 
combination with p65, TTP, MEKK1kd (kinase domain) or MEKK1fl (full length) expression plasmids as indicated and luciferase expression levels were 
analyzed. *, p<0.05; **, p<0.01, compared to the p65 induced sample; B) HEK 293 cells were transfected with 5xNF-κB-luc together with p65 and in 
combination with either MEKK1 D1369A (kinase domain mutant) or MEKK1 PHDmut (E3 ligase domain mutant) expression plasmids. Luciferase 
activities were assessed in the absence (EV) and presence of TTP. *, p<0.05; ***, p<0.001, compared to the respective empty vector (EV) samples. C) 
HEK 293 cells were transfected with expression plasmids for TTP and p38α (left panel) or TTP and MEKK1kd (kinase domain; right panel) and either 
left untreated (control) or treated with the MAPK inhibitors SB203580 (p38 inhibitor), SP600125 (JNK inhibitor) or PD98059 (MEK1 inhibitor) for 1 hour. 
Whole cell lysates were analyzed for TTP expression and “patterning” by Western blotting. 
 
 
downstream kinases such as ERK, JNK or p38α account for the indirect MEKK1 triggered TTP inhibition, 
we analyzed the p38α and MEKK1 mediated TTP modifications and resulting molecular patterning in the 
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presence of ERK, JNK and p38 inhibitors. As shown by the Western Blot in Fig. 13T (C) the p38 inhibitor 
SB203580 had a dampening effect on p38α-mediated TTP phosphorylation (left, second lane) while the 
inhibitors for JNK (SP600125) and ERK (PD98059) showed no effect, supporting the specificity of the 
inhibitors. Moreover, none of the inhibitors applied could prohibit the strong molecular shift of TTP 
triggered by the coexpression of the MEKK1 kinase domain (Fig. 13T, panels, right side).  Based on the 
above  results  we  hypothesized  that  MEKK1  as  well  as  p38α  physically  interact with TTP which was 
 
 
 
 
 
 
 
 
Fig. 14T: MEKK1 physically interacts with TTP and phosphorylates its N-terminus. A, left) HEK 293 cells were transfected with Myc-TTP in 
combination with either empty vector (EV) or HA-tagged MEKK1 and MEKK1 was immunoprecipitated. Co-precipitated TTP was analyzed by Western 
Blotting (upper panels). The lower three panels represent the input control. A, right) HEK 293 cells were transfected with Myc-TTP in combination with 
Flag-p38α what was immunoprecipitated using an anti-Flag matrix. Coimmunoprecipitation of TTP as well as the amount of precipitated p38α was 
assessed by Western Blotting (upper two panels), the input control is shown in the lower three panels. B) HEK 293 cells were transfected with TTP, 
TTPZnC or TTPZnN expression plasmids in combination with either empty vector (EV) or M1 (MEKK1 kinase domain only) vectors. Cell lysates of samples 
coexpressing MEKK1kd were devided and one half was treated with calf intestine alkaline phosphatase (CIAP) for 15 minutes. Expression of TTP and of 
TTPZnC and TTPZnN as well as their molecular shift was analyzed by 5-12% gradient SDS-PAGE and Western Blotting. 
 
 
subsequently shown by coimmunoprecipitation in HEK 293 cells (Fig. 14T, A). To further determine 
whether phosphorylation is responsible for the special molecular patterning of TTP, we analyzed the 
molecular shift of the protein before and after treatment with calf intestine alkaline phosphatase (CIAP).  
As shown by the Immunoblot in Fig. 14T (B, top panel), phosphatase treatment reversed the molecular 
weight shift of TTP, indicating that it is indeed due to phosphorylation. Furthermore, the same molecular 
weight shift and CIAP-mediated reversion could be observed when the TTPZnN construct was used instead 
of full length TTP, whereas MEKK1 did not affect the TTPZnC mutant construct (Fig. 14T, B, bottom 
panels), indicating that MEKK1 posphorylates the N-terminal part of TTP.  
The initial step in TNFR signaling is the assembly of a multicomponent receptor-associated cytoplasmic 
signaling complex immediately after TNFR engagement. Key players within this multiproteincomplex are 
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the TRAFs serving as E3 ubiquitin ligases and adaptors that recruit and activate protein kinases such as 
TAK1 and MEKK1, which in turn activate IKKs and JNK, respectively. In this context it is important to note 
that TNFR1-induced JNK activation strongly depends on activated MEKK1 which is facilitated by TRAF2 
mediated K63-linked ubiquitination.  
Based on this as well as our finding that MEKK1 and TTP physically interact, we aimed to examine 
whether TRAF2 is capable to form a complex with TTP. Coimmunoprecipitation in HEK 293 cells unveiled 
that TTP indeed coprecipated with TRAF2 (Fig. 15T, A).  When  we tested whether TRAF2 is able to act as  
 
 
 
 
 
 
Fig. 15T: TRAF2 physically interacts with TTP and triggers its ubiquitination which is enhanced in the presence of MEKK1. A) HEK 293 
cells were transfected with Myc-TTP in combination with either empty vector (EV) or HA-tagged TRAF2 which was precipitated using an α–HA matrix. 
Amounts of TRAF2 as well as coprecipitated TTP were analyzed by Western Blotting (upper two panels), the input control is shown in the lower two 
panels. B) HEK 293 cells were transfected with Flag-TTP, HA-TRAF2 and M1 (MEKK1 kinase domain) expression plasmids in the presence (+) or 
absence (-) of a wild type-ubiquitin (wt-Ubi) expression vector as indicated. Ubiquitinated proteins were precipitated under denaturating conditions 
using Ni-NTA-beads and the presence of polyubiquitinated TTP was assessed before (-MG132) and after treatment with MG132 (6 hours) by 
immunoblot analysis (left panels). The corresponding input controls are depicted within the right panels. 
 
 
 
 
an E3 ubiquitin ligase towards TTP, we found that TRAF2 can facilitate polyubiquitination of TTP, which is 
further enhanced upon coexpression of the MEKK1 kinase domain (Fig. 15T, B). Furthermore, we 
observed that proteasome inhibition by MG132 had no effect on TTP-ubiquitination, raising the possibility 
that attached ubiquitin chains might be K63-linked (Fig. 15T, B, left, bottom panels). 
To follow up on the nature of ubiquitination we utilized mutated versions of His-tagged ubiquitin (K48R, 
K63R) and tested their potential to ubiquitinate different TTP mutants in the presence or absence of 
TRAF2 and MEKK1. Whereas no ubiquitination took place in the absence of TRAF2 and MEKK1 (Fig. 16T, 
left panel), the full length TTP protein, as well as the TTP mutant TTPZnN underwent polyubiquitination 
when MEKK1 and TRAF2 were coexpressed. Interestingly, only the K48R mutant triggered ubiquitination, 
whereas the TTP mutant TTPZnC was not ubiquitinated (Fig. 16T, right panel). 
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Fig. 16T: TTP-N-terminal phosphorylation by MEKK1 is a 
prerequisite for K63-linked, TRAF2-mediated ubiquitination of its 
zinc-finger. HEK 293 cells were transfected with empty vector (EV), 
Flag-TTP or the TTP mutants Flag-TTPZnC and Flag-TTPZnN together with 
mutated version of His-tagged ubiquitin (K48R or K63R) as indicated and 
either without (left panels) or with (right panels) expression plasmids for 
MEKK1kd (kinase domain) and HA-TRAF2. Ubiquitinated proteins were 
precipitated under denaturating conditions using Ni-NTA-beads, and their 
presence analyzed by Western Blotting. The input control is shown in the 
lower three panels. 
 
 
 
In the course of our experimental set-up for in 
vivo ubiquitination assays we observed that 
ectopic expression of different combinations of 
TTP, MEKK1 and TRAF2 variably influenced 
cell morphology and growth in HEK 293 cells. 
As shown in Fig. 17T (A), the combined 
ectopic expression of TTP, TRAF2 and the 
kinase domain of MEKK1 alleviated cell growth 
which was further enhanced upon additional 
overexpression of wt-ubiquitin (Fig. 17T, A, 
bottom row, last pictures). Note, that when 
the MEKK1 kinase domain construct was 
exchanged with full length MEKK1, cell growth 
was completely unaffected. In addition, only 
the TTPZnN mutant construct but not the TTP-
N-terminus-only had an effect on cell growth 
and morphology, which resembled the 
appearance of cells undergoing apoptotis (Fig. 
17T, B). Cell growth, differentiation and 
apopotsis are processes that are mainly 
modified by the accurately timed interplay between NF-κB and JNK signaling. Onset of the JNK signaling 
cascade through e.g. the activation of MEKK1 results in the phosphorylation of JNK, finally leading to AP-1 
mediated target gene expression. When we analyzed p-JNK levels after ectopic expression of TTP in HEK 
293 cells we found that the activity of JNK was enhanced by elevated levels of TTP, whereas total JNK 
levels were not affected (Fig. 18T, A). This observation was further supported by AP-1-dependent 
reporter gene assays, where TTP overexpression led to upregulation of AP-1 dependent luciferase 
expression in a dose dependent manner (Fig. 18T, B). Conversely, TTP k.o MEF displayed strongly 
impaired JNK activation at basal as well as under TNFα stimulated conditions while, comparable to HEK 
293 cells, the total JNK levels were not influenced (Fig. 18T, C).  In addition, AP-1 dependent reporter 
analysis in MEFs supported the prior findings: ectopic TTP expression led to enhanced AP-1 promoter 
activity in both wt as well as TTP k.o MEF, whereas overall luciferase levels were significantly lower in TTP 
k.o compared to wt MEF (Fig. 18T, D).  
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Fig. 17T: Coexpression of TTP, MEKK1 kd (kinase domain) and TRAF2 influences cell growth in HEK 293 cells. A) HEK 293 cells were 
transfected with either empty vector (EV), TTP, TRAF2, MEKK1 full length (M1 fl), MEKK1 kinase domain only (M1 kd) or with different combinations of 
these expression plasmids, without (control) or together with an expression vector for wt-ubiquitin, as indicated. B) HEK 293 cells were transfected with 
the TTP-constructs TTP-Nterminus only (top pictures) or TTPZnN (bottom pictures) together with either empty vector (EV), TRAF2, MEKK1 kd (kinase 
domain; M1 kd) or MEKK1 kd  and TRAF2 expression plasmids in combination. Phase contrast pictures were taken 24 hours post transfection. 
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Fig. 18T: TTP influences JNK and AP-1 activity. A) HEK 293 were transfected with either empty vector (EV) or a TTP expression plasmid and 
stimulated with TNFα for the indicated time points. Whole cell extracts were analyzed for activation of JNK (P-JNK, left panel) as well as for total JNK 
levels (right panels) and the presence of transfected TTP (α-myc) by Western Bloting. GAPDH is shown as loading control. B) HEK 293 cells were 
transfected with an AP1-luc reporter alone (control) or in combination with increasing amounts of a TTP expression plasmid. Depicted are mean relative 
luciferase levels normalized to cotransfected β-galactosidase. **, p<0.01; ***, p<0.001, compared to the control sample. C) wt and TTP k.o MEF were 
stimulated with TNFα for the indicated time points and whole cell lysates were subjected to Western Bloting and analyzed for activated JNK (P-JNK; top 
panels) as well as for total JNK-levels (bottom panels). β-actin represents the loading control. D) wt and TTP k.o MEF were transfected with an AP1-luc 
reporter alone (control) or in combination with a TTP expression plasmid. Luciferase expression was normalized to cotransfected GFP. *, p<0.05; **, 
p<0.01. 
 
 
 
 
 
In the light of the above results we analyzed the potential of TTP to influence cell growth and/or 
apoptosis in primary HUVEC. We generated a recombinant adenovirus for expression of myc-tagged TTP 
under the control of the tetracycline responsive promoter (tet-OFF system, where expression of the 
transgene can be suppressed in the presence of doxycyclin [109]). Adenoviral-mediated overexpression of 
TTP did not influence HUVEC viability at low protein levels (Fig. 19T, part AdV 1/100). Interestingly, the 
concomitant stimulation of the cells with TNFα led to programmed cell death reflected by a high 
percentage of Annexin V positive cells (Fig. 19T, AdV 1/100, 16 hours time point; protein levels checked 
by Western Blot are shown in the insert). Note that TNFα stimulation in controls (cells infected with 
adenovirus where TTP expression was suppressed by doxycycline) did not result in any changes (Fig. 19T, 
part AdV 1/100, right three bars). Importantly, when TTP expression levels were increased, apoptosis 
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occurred completely independent of TNFα costimulation (Fig. 19T, part AdV 1/10, left three bars, 
corresponding TTP expression levels shown in the insert).  
 
 
 
           
 
 
Fig. 19T: TNFα and TTP synergistically induce apoptosis in primary HUVECs. HUVECs were infected with increasing amounts of TTP-
adenovirus (AdV 1/100 and AdV 1/10) and grown for 24 hours in medium containing no (-Dox = cells express ectopic TTP) or 4nM Doxycycline (+Dox 
= cells do not express ectopic TTP). Cells were stimulated with TNFα for the indicated time points and Annexin V positive cells were assessed by FACS 
analysis. TTP expression levels achieved by adenoviral transduction were analyzed by Western Blotting and are depicted in the insert. The red line 
represents the threshold of the background settings. Note that low TTP expression levels induce apoptosis only in synergism with 16 hours of TNFα 
stimulation. 
 
 
In summary, the presented data suggest that TTP has at least two functions: First, TTP mediates 
degradation of messenger RNAs, ensuring the rapid and accurate downregulation of proinflammatory 
mediators; second, TTP is involved in the inhibition of the prosurvival pathway NF-κB through impairing 
p65 nuclear translocation, and furthermore it acts as a trigger in the onset of apoptosis. This new mRNA-
decay-independent function of TTP is due to expression levels and posttranslational modifications. These 
modifications might differentially regulate its involvement in the crosstalk between NF-κB and MAPK 
signaling, thus constituting a trigger that ensures the functional switch from the RNA-destabilizer to the 
signaling-balancer (Fig. 20T). 
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4. DISCUSSION 
 
 
 
In the last decade substantial progress has been made towards elucidating negative regulatory 
mechanisms that function in the appropriate termination of the inflammatory response. Evidence has 
accumulated that resolution is already set early in the activation phase of the response, by so called 
immediate-early and early genes that act as gateways for the subsequent downregulation of 
proinflammatory gene expression. Elucidation of these feedback mechanisms and its contributors is of 
great importance for the understanding of acute versus chronic inflammation and for novel strategies of 
therapeutic intervention. 
In the course of our search of immediate early response genes with potential negative regulatory function 
in HUVEC we found Tristetraprolin. It is the prototype of a class of CCCH-zinc finger proteins and is 
rapidly induced by the proinflammatory agents LPS, IL-1 and TNFα. Its expression pattern exhibits 
classical features of an immediate early gene in HUVECs. Its mRNA levels accumulate within 30 minutes 
of cytokine induction and drop to undinduced levels approximately within the same time period. 
Remarkably, induction by IL-1 and TNFα leads to comparable upregulation and kinetics of TTP mRNA 
while treatment with LPS results in a much slower response with mRNA levels peaking 90 minutes after 
induction, where TTP levels have already dropped to a minimum upon cytokine treatment. A possible 
explanation for this diverging kinetics might be the fact that, although LPS, IL-1 as well as TNFα induced 
signaling cascades converge on a common IκB kinase complex that finally activates NF-κB, the upstream 
components are mainly receptor specific. This leads to a timed and signal specific activation of target 
gene expression dependent on the cell’s environmental demands.  
Another important aspect in the initial analysis of TTP expression in HUVECs was the matter of induced 
protein accumulation and stabilization. Detectable protein levels emerge shortly after accumulation of the 
TTP transcript. Important to note is that the protein does not undergo such a rapid turnover compared to 
its mRNA. Conversely, the protein is stabilized and accumulates over around 3-4 hours of TNFα 
stimulation, which is most likely facilitated by posttranslational modifications, since the protein undergoes 
a heavy shift in its molecular weight. This is further supported by earlier studies in various murine as well 
as human cell types, were it was shown that the molecular weight shift results from hyperphosphorylation 
of the protein [47, 50]. Nevertheless, after this period of stabilization, TTP protein levels drop until the 
initial undetectable state is reached. This decrease is due to proteasomal degradation since its inhibition 
by MG132 effectively blocks its degradation. Interestingly, the addition of MG132 does not lead to an 
accumulation of TTP upon uninduced conditions (data not shown), which is either due to the lack of 
active kinases that account for hyperphosphorylation and stabilization, or to an extremely high TTP mRNA 
turnover preventing translation. The notion that Tristetraprolin might function as a negative feedback 
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regulator emerged concomitantly with the initial finding that TTP regulates the levels of TNFα mRNA 
posttranscriptionally, and that its biosynthesis is induced by the same agents that stimulate TNFα 
production itself [19]. Nevertheless, evidence has accumulated that TTP might have a broader function. 
Examples include the influence on other RNA binding proteins, e.g. the KH-type splicing regulatory protein 
(KSRP) [110], as well as the proposed multifunctional activity in the control of glucocorticoid mediated 
gene expression [111].  
Here we show that TTP is involved in the negative transcriptional regulation of promoters containing 
NF-κB binding sites in different cell types. TTP inhibits the induced activity of these promoters about 70-
95% while the influence on the basal levels fluctuates below 50%. This might be explained by the fact 
that NF-κB constitutively shuttles between cytoplasm and nucleus [69] leading to a basal promoter 
activity with its magnitude being determined by the actual situation and condition of the cell. The negative 
regulatory role of TTP is further supported by the analysis of TTP deficient mouse embryonic fibroblasts 
as well as by siRNA mediated knock down of endogenous TTP in HUVEC.  
TTP exhibits a dose dependent effect on NF-κB, with only ~7ng of transfected TTP expression 
plasmid resulting in half-maximal reduction of promoter activity, an amount that was below our detection 
limit on Western Blots (whereas endogenous TTP could be detected at least after stimulation in other cell 
types; data not shown). This indicates that the transfected amounts are well below the induced, 
endogenous TTP levels of other cell types. Lai and colleagues have shown previously [34] that the 
overexpression of human TTP exhibits different effects on the degradation of TNFα mRNA, dependent on 
its expression levels: while low levels of TTP efficiently destabilize the TNFα message, they observed that 
higher levels lead to the stabilization of the mRNA, which is explained by the possibility that TTP might 
form inactive dimers at higher concentrations or sequester components of the RNA degradation 
machinery. 
Initially we hypothesized that TTP might trigger the down-regulation of the expression of one ore 
more components of the NF-κB signaling pathway through its known mRNA destabilizing activity. 
However, the use of TTP constructs, which either carry a mutation in the zinc-finger domain (C124R) that 
impairs ARE binding and mRNA degradation, or lack the N- and C-terminal domains (TZF), provided 
evidence that TTP inhibits NF-κB independent of its well-described mRNA destabilizing function. The fact 
that the RNA binding mutant C124R does not diminish, but rather augments TNFα mRNA levels has 
already been observed by Lai and colleagues and is further confirmed in our experiments. It can be 
explained by the inhibition of mRNA turnover due to dominant-negative functions of this mutant [112]. 
Further examination of the mechanism of TTP action revealed that TTP influences the activation of NF-κB 
at the level of p65: no upstream mediator of NF-κB signaling (TRAF2, TAK1/TAB1, IKK2) overcomes this 
strong, inhibitory TTP effect, IκBα degradation is not affected and overexpression of the known p65 
nuclear co-activators CBP, p300 and MSK1 does not prohibit TTP action. Besides, neither total p65 protein 
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amounts nor mRNA levels are influenced and no physical interaction of TTP with p65 can be 
demonstrated by coimmunoprecipitation (data not shown). However, the results of follow-up experiments 
uncovered that the nuclear import of NF-κB/p65 is affected by TTP: biochemical analysis demonstrated 
that p65 appears in the nucleus 15 minutes post TNFα stimulation in control cells, whereas TTP 
transfected cells show a severely impaired nuclear translocation. Densitometric analysis of nuclear p65 
levels revealed that already under unstimulated conditions less p65 is present in the nucleus and the 
difference gets even more evident after stimulation with TNFα, in agreement with the results obtained by 
reporter gene assays. These findings were further confirmed at the single-cell level by immunofluorescent 
analysis of endogenous p65 in primary HUVEC.  
In line with the promoter studies performed in TTP k.o MEF, we found that p65 exhibits increased 
nuclear localization under unstimulated conditions in these cells. Here, the lack of TTP seems to allow 
enhanced nuclear shuttling of NF-κB, leading to a “pre-stimulated” situation that is reflected by the 
upregulation of certain NF-κB target genes. It has to be pointed out that the target genes analyzed in 
untreated TTP k.o cells provide an insight into the prestimulated situation generated by TTP deficiency. It 
is in all probability that under e.g. TNFα stimulated conditions other and/or additional target genes might 
be differentially regulated. The fact that only a subset of NF-κB regulated genes is affected in our 
experiments might be explained by the complexity of NF-κB activation: the selective transcriptional onset 
of specifically required target genes is dependent on the formation of distinct NF-κB dimer/heterodimer 
combinations, the abundance and distribution of essential cofactors as well as the epigenetic regulation of 
the accessibility of the promoters. The proper timing and interplay of these components may facilitate the 
differential expression of a plethora of NF-κB dependent genes.     
Our analysis revealed that the “ARE-less” NF-κB targets RANTES, Gadd45β and TRAF1 are 
upregulated in TTP k.o MEF. RANTES, a chemokine that appears chemotactic for T cells, eosinophils, and 
basophils, plays an active role in recruiting leukocytes to inflammatory sites.  TRAF1 is a member of the 
TNFR2 signaling complex, which exerts multiple biological effects on cells such as proliferation, cytokine 
production, and cell death. Gadd45β in turn is known to be involved in the regulation of DNA repair and 
cell cycle control. In the light of the fact that TTP k.o cells grow somewhat faster than wt MEF, it appears 
interesting that all these genes have been connected to the regulation of cell proliferation or apoptosis, a 
decision that is predominantly controlled by the crosstalk of NF-κB with JNK signaling,  which will be 
discussed later.  
Concerning the mechanism of TTP mediated inhibition of the nuclear import of NF-κB it is interesting 
to note that in drosophila, nup214, a component of the nuclear pore complex (NPC), has been implicated 
in the modulation of NF-κB activation. Nup214 is a member of the so called FG-Nups that provide 
specificity and abundance of transport factor binding sites at the NPC and have been shown to facilitate 
the karyopherin-cargo movement across the nuclear pore. Nup214 mutants impaired the nuclear 
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accumulation of the p65/p50 homologues Dorsal and Dif after bacterial challenge [113]. A separate study 
showed that TTP was able to interact with nup214 in THP-1 cells [114]. It is therefore tempting to 
speculate that the mechanism of TTP action might involve the selective prevention of NF-κB import via 
regulation of a Nup214-containing nuclear pore. Thereby selectivity might be achieved through the nature 
of the monopartite p65 NLS as opposed to e.g. the bipartite leader of p53 which, if exchanged, abrogates 
the inhibitory function of TTP.  
The aim of further investigations was to identify potential upstream triggers that control TTP function. 
Meanwhile it is quite well established that hyperphosphorylation of TTP occurs at multiple sites which 
were determined by site directed mutagenesis and mass spectometry [54]. In addition, different kinases 
have been shown to phosphorylate TTP in intact cells and/or in cell-free systems, including the MAPKs 
ERK, p38 as well as JNK [52, 53, 115, 116]. However, effects of phosphorylation on TTP function(s) 
remained largely elusive compared to its number of phospho-sites and predicted kinases. The only kinase 
which has been elucidated in detail so far is p38α-MK2, which mediates phosphorylation of TTP and 
contributes to LPS induced accumulation of TTP in murine macrophages [45-47]. Furthermore it has been 
shown that dephosphorylated TTP binds more tightly to AU-rich elements than phosphorylated TTP [116].  
In our studies predicted TTP kinases as IKK1, PKA, PKCα, PKCβ, PKCγ and PKCζ were tested for their 
potential to compensate the inhibitory TTP effect, but none of these kinases prohibits TTP action in 
respect to NF-κB activity (data not shown). However, we found that the MAP3K MEKK1, which has not 
been associated with TTP phosphorylation yet, exhibits the ability to prevent TTP from dampening NF-κB 
activity. MEKK1 is an upstream kinase of p38α, which was shown to phosphorylate TTP and counteract its 
RNA-destabilizing function. For this reason we tested p38α for its potential to compensate for TTP activity 
and observed that it can not prevent TTP from inhibiting NF-κB. Together with the fact that the RNA 
binding deficient TTP mutant C124R inhibits promoter activity as well, this substantiates the possibility 
that TTP has a function that differs from its transcript-degrading ability. Furthermore this indicates that 
MEKK1 mediated TTP control is not due to signaling via p38α. This is further supported by the fact that 
also co-expression of the p38α upstream kinase MEK3 does not result in any changes of the TTP effect. 
In addition, both p38α as well as MEKK1 lead to an electrophoretic shift of the protein but with a 
completely differential patterning of molecular weight species. While the additition of a p38 inhibitor leads 
to the ablation of p38α induced TTP-phosphorylation it does not alter the molecular pattern of the 
MEKK1-mediated protein-shift, nor do ERK or JNK inhibitors, supporting the idea of a direct MEKK1-TTP 
interaction.     
Together these findings indicate that TTP acts as inhibitor of NF-κB signaling at the transcription 
factor level, while the MAP3K MEKK1 seems to act as upstream trigger that “pulls TTP out of its inhibitory 
scenario”. Surprisingly, the combined expression of p38α and MEKK1 does not alter TTP inhibitory 
function at all, which might be explained by the fact that upon overexpression, MEKK1 predominantly and 
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possibly with higher affinity, phosphorylates its direct downstream target p38α that in rapid succession 
leads to phosphorylation of TTP resulting in the TTP effect seen for p38α coexpression. Besides, it might 
be possible that p38α mediated TTP phosphorylation prevents the interaction with MEKK1. MEKK1 is a 
195kD protein containing a C-terminal kinase domain as well as a N-terminal PHD domain that acts as E3 
ligase. The observation that only the kinase domain of MEKK1 efficiently blocks the inhibitory TTP effect 
might be due to the fact that full length MEKK1 undergoes autoubiquitination dependent on its kinase 
domain, which finally leads to the inactivation of its catalytic function [117]. The further finding that a 
kinase-dead MEKK1 mutant is completely inactive in regard to TTP proves that the kinase domain is 
sufficient to account for TTP control. Furthermore, the physical interaction of TTP and MEKK1 as well as 
the fact that phosphatase treatment leads to a complete reversion of its electrophoretic mobility shift, 
confirms the assumption that MEKK1 phosphorylates TTP. MEKK1 is a multifunctional protein containing 
several domains including the above described PHD and catalytic domains. Additionally important regions 
include the activation loop comprising phsophorylation sites, two ubiquitin interacting motifs (UIMs), 
binding sites for e.g. the MAPK ERK as well as a caspase cleavage site. These are indispensable and 
account for the multifunctionality of the protein. This might additionally explain, why full length MEKK1 as 
well as full length MEKK1 with a mutated PHD domain, show a weaker effect on TTP. Interestingly, 
MEKK1-mediated phosphorylation occurs at the N-terminal part of the TTP protein, a region that is not 
conserved among the members of the well described TIS-family of proteins which all exhibit the ability to 
destabilize mRNAs. This might be an indication for a TTP specific function, acquired in the course of 
evolution where TTP may have structurally and functionally diverged from an initially common ancestor.  
Regarding TNFR engagement, it is known that MEKK1 activation as well as its specific function are not 
only dependent on autophosphorylation and autoubiquitination but are strongly context dependent and 
rely on the formation of different complexes as well as the abundance of cofactors. These include TRAF2, 
3, and 6 which are recruited to the receptor and facilitate the subsequent activation of the MAP3 kinases 
MEKK1 and TAK1 that culminate in MAPK and IKK activation. Specific activation of the latter is achieved 
through K63-linked autoubiquitination of TRAF2 and TRAF6, the degradation of inhibitory proteins and the 
appropriately timed release and activation of distinct signaling complexes, containing TAK1-TRAF6 or 
MEKK1-TRAF2, which trigger the onset of p38 or JNK activity leading to programmed cell death [118]. In 
this context it is important that MEKK1 is known to activate various downstream MAP2Ks leading to either 
cell proliferation or apoptotic signaling. Whereas the promotion of cell survival depends on the intact full 
length MEKK1 protein that is associated with the membrane-bound receptor complex, apoptotic signaling 
is dependent on caspase cleavage of MEKK1 resulting in a COOH-terminal catalytic MEKK1-fragment that 
localizes to the cytosol and promotes caspase and JNK activation. Therefore, our observation that the 
kinase domain of MEKK1 sufficiently accounts for the phosphorylation of TTP, which is a prerequisite for 
its K63-linked-TRAF2-mediated polyubiquitination, makes it tempting to speculate that TTP might, under 
specific circumstances, be a “multicomplex” member and contributes to the regulated balance between 
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NF-κB and JNK signaling. TTP inhibits not only NF-κB-survival signals by blocking p65 translocation but 
also interacts with its regulatory cofactors MEKK1 and TRAF2 to jointly facilitate the onset of proapoptotic 
JNK signaling. Overexpression of TTP clearly enhances phospho-JNK levels and AP-1 promoter activity in 
HEK 293 cells and the absence of TTP leads to the converse scenario in TTP k.o MEF: JNK activation is 
strongly impaired in these cells, which is reflected by the attenuation of AP-1 promoter activity. Together 
with our finding that p65 levels are elevated in these cells, this supports the notion that the absence of 
TTP might lead to a shift in the balance for the benefit of prosurvival signaling. This is supported by the 
fact that TTP k.o MEF grow faster compared to wt cells, as well as by the specific upregulation of a subset 
of NF-κB dependent genes that are all connected to the regulation of cell proliferation or apoptosis, as 
discussed above. 
The proapoptotic activity of TTP was already described earlier [119, 120] as well as the potential of 
the TTPZnN domain to induce programmed cell death synergistically with TNFα in a variety of cell types but 
the underlying regulatory mechanism(s) remained elusive. Interestingly, we find that MEKK1-TRAF2 
mediated posttranslational modifications of TTP occur in its ZnN-terminal region, which further lead to an 
obvious decrease of cell viability in HEK 293 cells, supporting the idea of a specific TTP-MEKK1-TRAF2 
triggered onset of proapoptotic events. Furthermore, high levels of ectopically expressed TTP lead to 
TNFα independent apoptosis in primary HUVEC, whereas low levels of TTP induce apoptosis exclusively in 
synergism with TNFα, which is in addition strongly dependent on the duration of TNFα induction.  
Together this seems suggestive of a scenario where TTP might be tightly regulated by MEKK1-TRAF2 
controlled posttranslational modifications that determine at least in part its proapoptotic activity.  
     Taken together, these observations reveal an additional, and, to our knowledge, novel activity for TTP. 
To date we can not completely exclude that TTP triggers the activation or repression of other ARE binding 
proteins through protein-protein interactions, or that the loss of function mutation in the zinc-finger 
concerns only a subset of ARE containing targets. In this regard a recent finding revealed that TTP does 
not exclusively bind to ARE sequences, but additionally recognizes a non-ARE cis element in the MHC 
class I mRNA [121]. However, 3’-UTR analysis of this mRNA demonstrated a binding deficiency of the 
zinc-finger mutant as well, suggesting that the loss of function is not restricted to a certain ARE motif.  
In addition, the finding that the MAP3K MEKK1 leads to direct or indirect phosphorylation of TTP 
promoting its subsequent K63-linked polybuiquitination, finally affecting cell viability, could be important 
in vivo in multiple ways. Together with its well-described mRNA destabilizing function these complex 
relationships suggest that TTP may contribute to the regulation of NF-κB-mediated responses at least on 
two levels: through the destabilization of cytokine mRNAs (e.g. TNFα) , and through acting as specific 
“balancer” between the choice of either NF-κB dependent survival and differentiation, or death via TNFα 
induced apoptosis (Fig. 20T). Therefore TTP might be indispensable for the appropriately regulated 
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negative feedback control during a variety of NF-κB-dependent pathophysiological situations and serves 
as a perfect target for specific therapeutic interventions. 
 
 
 
 
Fig. 20T: Model: TTP as “bifunctional” balancer in the TNFα induced NF-κB response. NF-κB activity can be separated into 
different activation states upon cytokine induction (red line), as well as in different TTP-regulated phases (Table on top). In the 
uninduced state the basal levels of gene expression as well as TTP itself are kept low. Upon TNFα stimulation NF-κB -mediated 
transcription is enhanced, mRNAs are stabilized which is achieved through the activation of kinases as e.g p38α that mediate 
phosphorylation of TTP leading to a block of its RNA degrading ability. Hyperphosphorylated TTP accumulates, the protein is 
stabilized and NF-κB-target genes are unaffectedly expressed, mediating an appropriate cellular response. At this phase a TTP-
functional switch might occur, at least partly regulated by posttranslation modifications as ubiquitination and/or other modifications, 
resulting in the transcriptional control of NF-κB and its appropriate crosstalk with apoptotic JNK signals. This controlled balance 
might constitute a “basic-support-mechanism” during the active state of inflammation and might finally facilitate the unhindered, 
correct termination of the response. In the end the removal of TTP-modifications, through for example phosphatases like PP2A [51], 
results in a functional reversion and in high levels of “unmodified” TTP that finally, following the “back-to-the-RNA-degrading-roots”-
principle, facilitate the rapid decrease of proinflammatory mRNAs leading to the resolution of the response reconstituting the initial, 
basal state of the healthy cell. 
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5. MATERIALS AND METHODS 
 
 
5.1. Plasmids & Cloning 
 
5.1.1. Plasmids 
 
Reporter plasmids 5xNF-κB-luc, p53-luc, NFAT-luc, pFR-luc as well as pFc-MEKK were obtained from 
Stratagene (PathDetect). IL-8-luc, the truncated version of the IL-8 promoter, TF-luc as well as 
expression vectors for p65, IKK2 and TAK1 have been described elsewhere [122-124]. TAB1 was 
purchased from Invitrogen. The Gal4-p65 mutant constructs (p65*: p65 aa286-551; M1: p65 aa286-520, 
M2: p65 aa521-551; M3: p65 aa450-520) were kind gifts from L. Schmitz [125] as well as the 
pRC/CMVp65 plasmid used for generation of p53NLSΔNLSp65. SV40NLSp65 and SV40NLSΔNESp65 were 
gifts from Shao-Cong Sun [126]. Expression plasmids for TRAF2 and CBP/p300 were kindly provided by H. 
Wajant and C.Brostjan, respectively. The wt-HA-MEKK1 expression vector as well as mutant constructs of 
MEKK1 (pCEP4 HA-MEKK1 D1369A and HA-MEKK1 C433A/487A) were obtained from Tony Hunter’s lab 
[127], IKKγ was provided by S. Gosh and the pMT123 HA-Ubiquitin-Octamer and His-tagged-ubiquitin 
expression vectors were made available by D. Bohmann and are described elsewhere [128]. The basic 
vectors pAdEasyTetOFFrev as well as pShuttle TripTet-Lac-BamHI, used for the generation of the TTP-
Adenovirus, were kindly provided by G. Akusjärvi [109]. 
 
5.1.2. Cloning and Maps 
 
pCMV-MycTTP (TZF/C124R) 
 
 
 
 
 
 
 
 
 
pCMV-MycTTP (Map.1) was generated by PCR from the RZPD clone IRAK p961M0614Q2 and ligated into  
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the EcoRI/SalI sites of pCMV-myc (Clontech). pCMV-MycTZF (aa97-173; Map.2) and pCMV-MycC124R 
(Map.3) were generated by subcloning and in vitro mutagenesis, respectively. 
 
 
pCDNA3-Flag-TTP (Map.4) 
 
 
 
 
 
 
 
 
The coding sequence of human TTP, corresponding to AA 1-326, was amplified by PCR from the vector 
pCMV-MycTTP (Map.1) using the primers TTP 1-326 fwd/rev (see 5.1.3). The 926bp PCR product was 
ligated into pCRII-Topo (Invitrogen) followed by restriction with EcoRI and XhoI and ligation into the 
respective sites of pcDNA3-Flag. 
 
 
 
pCDNA3-Flag-TTPZnC  (Map.5) 
 
 
 
 
 
 
 
 
Amino Acids 97-326 of the human TTP coding sequence were amplified by PCR from the vector pCMV-
MycTTP (Map.1) using the primers TTP 289-981 fwd/rev (see 5.1.3). The ~700bp PCR product was 
ligated into pCRII-Topo (Invitrogen) followed by restriction with EcoRI and XhoI and ligation into the 
respective sites of pcDNA3-Flag. 
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pCDNA3-Flag-TTPZnN  (Map.6) 
 
 
 
 
 
 
Amino Acids 1-173 of the human TTP coding sequence were amplified by PCR from the vector pCMV-
MycTTP (Map.1) using the primers TTP 1-519 fwd/rev (see 5.1.3). The ~500bp PCR product was ligated 
into pCRII-Topo (Invitrogen) followed by restriction with EcoRI and XhoI and ligation into the respective 
sites of pcDNA3-Flag. 
 
pCDNA3-Flag-TTPTZF  (Map.7) 
 
 
 
 
 
 
 
Amino Acids 97-173 of the human TTP coding sequence were amplified by PCR from the vector pCMV-
MycTTP (Map.1) using the primers TTP-TZF fwd/rev (see 5.1.3). The ~230bp PCR product was ligated 
into pCRII-Topo (Invitrogen) followed by restriction with EcoRI and XhoI and ligation into the respective 
sites of pcDNA3-Flag. 
 
 
pCDNA3-Flag-TTPNterm  (Map.8) 
 
 
 
 
 
 
 
Amino Acids 1-100 of the human TTP coding sequence were amplified by PCR from the vector pCMV-
MycTTP (Map.1) using the primers TTP-Nterm fwd/rev (see 5.1.3). The ~300bp PCR product was ligated 
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into pCRII-Topo (Invitrogen) followed by restriction with EcoRI and XhoI and ligation into the respective 
sites of pcDNA3-Flag. 
 
 
pCDNA3-Flag-TTPCterm  (Map.9) 
 
 
 
 
 
 
 
Amino Acids 176-326 of the human TTP coding sequence were amplified by PCR from the vector pCMV-
MycTTP (Map.1) using the primers TTP-Cterm fwd/rev (see 5.1.3). The ~470bp PCR product was ligated 
into pCRII-Topo (Invitrogen) followed by restriction with EcoRI and XhoI and ligation into the respective 
sites of pcDNA3-Flag. 
 
 
pRC_CMVp53NLSΔNLSp65 (Map.10) 
 
 
 
 
 
 
 
 
 
 
 
A synthetic p53NLS linker (5’HindIII-3’NcoI; see 5.1.3) was fused to the N-terminus of p65. The p65 NLS 
sequence was cut out by BstEII-AleI restriction and exchanged with the same fragment from the 
pCDNA3.1/Myc-Hisp65NLSmut vector kindly provided by R. Fagerlund [71]. 
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pCDNA3.1-6xHis-TTP (Map.11) 
 
 
 
 
 
 
 
 
The human TTP coding sequence was obtained by EcoRI and XhoI restriction of the vector pCMV-MycTTP 
(Map.1) and ligated into the respective sites of the pCDNA3.1-HisA vector purchased from Invitrogen.  
 
pCDNA3.1-6xHis-TTPZnC  (Map.12) 
 
 
 
 
 
 
 
Amino Acids 97-326 of the human TTP coding sequence were cut out of the vector pCDNA3-Flag-TTPZnC 
(Map.5) using EcoRI/XhoI restriction. The ~700bp fragment was ligated into the respective sites of the 
pcDNA3.1-HisC vetor (Invitrogen). 
 
pCDNA3.1-6xHis-TTPZnN  (Map.13) 
 
 
 
 
 
 
 
Amino Acids 1-173 of the human TTP coding sequence were cut out of the vector pCDNA3-Flag-TTPZnN 
(Map.6) using EcoRI/XhoI restriction. The ~500bp fragment was ligated into the respective sites of the 
pcDNA3.1-HisC vector (Invitrogen). 
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5.1.3. Primer Sequences 
 
TTP 1-326 fwd (EcoRI)  5’-CGA ATT CAT GGA TCT GAC TGC-3’ 
TTP 1-326 rev (XhoI)  5’-CGC TCG AGT CAC TCA GAA A-3’ 
 
TTP 289-981 fwd (EcoRI) 5’-GAA TTC ACC TCC ACC ACC C-3’ 
TTP 289-981 rev (XhoI)  5’-CTC GAG TCA CTC AGA AAC AGA-3’ 
 
TTP 1-519 fwd (EcoRI)  5’-GAA TTC ATG GAT CTG ACT GCC ATC-3’ 
TTP 1-519 frev (XhoI)  5’-CTC GAG TTA CGC CAG GTC TTC G-3’ 
 
TTP-TZF fwd (EcoRI)  5’-GAA TTC ACC TCC ACC ACC CCC T-3’ 
TTP-TZF rev (XhoI)  5’-CTC GAG TTA CGC CAG GTC TTC GC-3’ 
 
TTP-Nterm fwd (EcoRI)  5’-GGA ATT CAT GGA TCT GAC TGC C-3’ 
TTP-Nterm rev (XhoI)  5’-CGC TCG AGT CAG GTG GTG-3’ 
 
TTP-Cterm fwd (EcoRI)  5’-GAA TTC GGC CAC CCT CCT-3’ 
TTP-Cterm rev (XhoI)  5’-CGC TCG AGT CAC TCA GAA AC-3’ 
 
p53NLS linker 
p53NLS sense: 
5’- AGC TTC CAC CAT GAA GCG AGC ACT GCC CAA CAA CAC CAG CTC CTC TCC CCA GCC AAA GAA GAA 
ACC AGC - 3’ 
p53NLS antisense: 
5’- CAT GGC TGG TTT CTT CTT TGG CTG GGG AGA GGA GCT GGT GTT GTT GGG CAG TGC TCG CTT CAT 
GGT GGA - 3’ 
 
 
5.2. Cell Culture 
 
5.2.1. Cell maintainance and Media 
 
HEK 293 cells and HeLa cells were obtained from ATCC, wild-type (wt) and TTP k.o MEF were kindly 
provided by PJ Blackshear. Cells were cultured in DMEM (Bio-Whittaker) supplemented with 10% FCS 
(Sigma), 2mM L-glutamine (Sigma), penicillin (100units/ml), and streptomycin (100µg/ml). Human 
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umbilical vein endothelial cells were isolated from umbilical cords as described [129] and maintained in 
M199 medium (Lonza) supplemented with 20% FCS (Sigma), 2mM L-glutamine (Sigma), penicillin 
(100U/ml), streptomycin (100µg/ml), and 0.25µg/ml fungizone, 5U/ml Heparin, and 25µg/ml ECGS 
(Promocell). 
 
 
5.2.2. Cytokines and Inhibitors  
 
Recombinant human and mouse TNFα were purchased from R&D systems and Biosource respectively. 
They were stored as 10 µg/ml stock in phosphate buffered saline (PBS) with 0.1% bovine serum albumine 
(BSA, Sigma) and used at a final concentration of 10ng/ml. IL-1 and LPS were stored in PBS/0.1%BSA 
and used at final concentrations of 10µg/µl and 500µg/ml respectively. The α-TNFα blocking antibody 
(R&D systems, AF-410-NA) was used at a concentration of 5µg/ml. 
The proteasome inhibitor MG132 (Affinity) was stored in DMSO as 10mM stock solution and used at a 
final concentration of 10µM. The MAPK inhibitors SB203580 (specific inhibitor of p38 MAPK), SP600125 
(selective JNK inhibitor) and PD98059 (specific inhibitor of MAP2K MEK1) were obtained from Tocris 
Bioscience. They were kept as 10mM stock solutions in DMSO and used at final concentrations of 10-
30µM as indicated. The transcriptional inhibitor ActinomycinD was stored as 1mg/ml stock in DMSO and 
used at a final concentration of 10µg/ml. 
 
 
5.2.3. Transfection Methods and Reporter Gene Analysis 
 
HEK 293 cells were transfected by the calcium phosphate method as described [130]. MEF as well as 
HUVEC were transfected using the polyethylenimine (PEI) method [131].  
For reporter gene assays, HEK 293 cells were grown in 24-well plates, MEF and HUVEC in 12-well plates. 
Cells were transfected as described with the indicated reporter and/or expression plasmids using 4µg total 
DNA. Cells were stimulated with TNFα (10ng/ml) for 16 hours.  
Cells were lysed 45-48 hours post transfection in 1xPassive Lysis buffer (Promega) for 30-45’ at RT. 
Lysates were analyzed for luciferase activity, which was normalized to β-galactosidase or GFP expression. 
The reaction mix for luciferase measurements contained 25mM Glycin-Glycin pH7.8, 10mM MgSO4, 2mM 
ATP, the injection mix was comprised of 25mM Glycin-Glycin pH7.8 and 0.2mM D-Luciferin (Roche) and 
measurements were accomplished using a Luminometer (Lumat, Berthold). β-galactosidase activity was 
determined by mixing the cell lysate with chlorophenolred-β-D-galactopyranoside (CPRG, Roche, 0.05% 
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w/v in PBS with 0.1% w/v BSA) followed by absorbance-measurement at 570nm in an ELISA reader (SLT 
340ATCC). GFP levels were determined by excitation-emission measurements (485nm/535nm) in the 
Wallac Victor2 1420 Multilabel Counter. 
All experiments were performed in triplicates, and are representative for at least three independent 
experiments. Luciferase values were normalized for cotransfected β-gal or GFP and are illustrated as 
mean fold induction. Error bars represent standard deviation of the mean.  
 
 
5.2.4. siRNA mediated knock down 
 
To elucidate the effect of diminished TTP levels on NF-κB promoter activity in HUVEC, we have used RNA 
interference. Therefore cells were grown in 12-well plates and transfected with the indicated reporter 
plasmid together with the stealth custom siRNA pool* for Zfp36 (Invitrogen, see Table I for sequences) 
using the PEI method.  
 
Table I: sequences of siRNA-oligos targeting human Zfp36 
Zfp36_1* 5’-ACA AGA CUG AGC UAU GUC GGA CCU U-3’ 
Zfp36_2* 5’-UGG AUC UGA CUG CCA UCU ACG AGA G-3’ 
Zfp36_3* 5’-CCU GGG AUC CGA CCC UGA UGA AUA U-3’ 
scrambled control 5’-ACA AGA GUG UGC AAU CUC GGA GCU U-3’ 
          *pool of 3 oligos 
 
 
Cells were harvested 48 hours post transfection and lysed in 1xPassive Lysis buffer (Promega) followed by 
analysis of Luciferase and GFP activities as described in 5.2.3. 
Luciferase values were normalized for cotransfected GFP and are illustrated as mean fold induction. Error 
bars represent standard deviation of the mean.  
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5.3. Recombinant TTP-Adenovirus  
 
5.3.1. Cloning and Recombination 
 
Cloning of pShuttleTripTetlac-MycTTP vector (Map.14) 
 
 
 
 
 
 
 
 
 
 
 
The human TTP coding sequence, N-terminally fused to a Myc-Tag, was amplified by PCR out of the 
vector pCMV-MycTTP (Map.1) using the primers BglII-TTPfwd (5’-CGA GAT CTC CAT GGC ATC AA-3’) and 
BglII-TTPrev (5’-GCA GAT CTT CAC TCA GAA ACA GA-3’). The ~1kb PCR product was ligated into pCRII-
Topo (Invitrogen) followed by restriction with BglII and ligation into the BamHI site of the 
pShuttleTripTetlac-BamHI vector. 
 
 
Generation of recombinant AdEasyTetOFF-MycTTP 
 
To produce the recombinant AdEasyTetOFF-MycTTP plasmid, the pShuttleTripTetlac-MycTTP (Map.14) 
vector was linearized with PmeI and cotransformed with the pAdEasyTetOFFrev (Berenjian, 2006) plasmid 
into BJ5183 bacterial cells via electroporation using the Biorad gene pulser. Settings were as follows: 
200Ω, 2.5kV,25µF. Freshly electroporated cells were incubated in 1ml LB medium at 37°C while shaking 
at 250rpm for 1 hour followed by plating onto LB-Kanamycin (50µg/ml) plates. Positive Clones were 
confirmed by PacI restriction digest and sequencing. 
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5.3.2. Virus propagation in HEK 293lac cells 
 
HEK 293lac cells [109] were grown in 6-well plates to 50% confluency and transfected with PacI 
linearized AdEasyTetOFF-MycTTP using the PEI transfection method. Cells were grown in the presence of 
4nM Doxycycline until plaque formation. To obtain a crude virus-lysate, cells were collected, washed with 
PBS and the cell pellet was resuspended in 1xHE buffer followed by 3x freeze-thawing in liquid nitrogen. 
The intact TTP sequence was confirmed at this stage by direct PCR on the crude virus lysate. For 
generation of the “concentrated, high titer” – adenovirus stock, HEK 293lac cells were grown on 40x 15cm 
dishes in the presence of 4nM Doxycycline to ~70% confluency. Cells were infected with 2µl of crude 
viral-lysate/dish and left until plaque formation. Pure virus was prepared as follows: infected cells were 
harvested in PBS, washed once and resuspended in 1xHE buffer. The cell-suspension was subjected to 3 
freeze-thaw cycles followed by a 1.45g/cm³-1,33g/cm³ CsCl step gradient centrifugation as described 
elsewhere [132, 133]. Subsequently, the accumulated virus was collected and dialysed twice against 0.5l 
of 20mM HEPES/50mM NaCl/40% glycerol at 4°C. The purified virus-stock was stored in aliquots at -80°C. 
 
1xHE-buffer:                                             
10mM HEPES 
1mM EDTA 
pH 7.5 
 
CsCl-gradient: 
1.33g/cm³ CsCl in 1xHE 
1.45g/cm³ CsCl in 1xHE 
 
 
5.3.3. Adenoviral Infection of HUVEC and FACS analysis 
 
To study a potential effect of TTP overexpression on programmed cell death in primary HUVECs, cells 
were grown on 6-well plates to ~90% confluency and infected with the AdEasyTetOFF-MycTTP 
Adenovirus (MOI=250). Infection was performed in M199 complete medium (see 5.2.1) for 4-6 hours in 
the presence or absence of 4nM doxycycline. Infected cells were stimulated with hrTNFα (10ng/ml final 
concentration) for the indicated time points and harvested at the latest 48 hours post infection. After 
trypsinization, the pellet was washed once followed by resuspension in 1xAnnexin binding buffer. 
For the assessment of apoptosis the resuspended cells were double-stained using 10 µL Annexin V-PE (BD 
Pharmingen; 1:10 diluted in 1xAnnexin Binding Buffer) and 5µl 7-AAD (eBioscience). Subsequently, the 
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samples were incubated for 15 minutes in the dark prior to analysis in the flow cytometer (BD - 
Excalibur). Data were analyzed using the CellQuestPro program. 
 
10xAnnexin binding buffer: 
0.1 M Hepes 
140mM NaCl  
25mM CaCl2
 pH=7.4  
 
 
 
5.4. Cell Extracts 
 
5.4.1. Total Protein Purification 
 
Generation of cell lysates using 1xPassive Lysis Buffer 
 
Cells were rinsed in PBS and collected by centrifugation, the pellet was resuspended in 1xPassive Lysis 
Buffer (Promega) supplemented with protease inhibitors (Complete Protease Inhibitor cocktail tablets, 
Roche) and incubated for 30 min on ice. Subsequently, insoluble fractions were removed by centrifugation 
at 13000rpm for 3 minutes at 4°C. 5xLämmli loading buffer was added to supernatants prior to loading on 
sodium dodecyl sulfate-polyacrylamide-gels and Western Blotting. 
 
Generation of cell lysates using Lämmli sample buffer 
 
Cells were rinsed in PBS, the pellet was resuspended in 2xLämmli Buffer and subjected to 3 freeze-thaw 
cycles (liquid nitrogen, 95°C) prior to loading on sodium dodecyl sulfate-polyacrylamide-gels and Western 
Blotting. 
 
 
5xLämmli buffer 
50% (v/v) Glycerin 
10% (w/v) sodium dodecyl sulphate 
0.4M Tris-HCl pH 6.8 
5mg Bromphenol blue 
10% (v/v) β-mercaptoethanol (Fluka) was freshly added before use 
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5.4.2. Cell Fractionation 
 
For p65 nuclear translocation and IκBα degradation, cells were grown and transfected in 6cm (HEK 293) 
or 10cm dishes (MEF). 48 hours post transfection cells were stimulated with 10ng/ml TNFα (mouse or 
human rTNFα, R&D systems) for the indicated time points. Cells were harvested and cytoplasmic and 
nuclear extracts were prepared as follows: cells were washed once with PBS followed by centrifugation at 
3000rpm for 3 minutes. Pellets were rinsed with ice cold buffer A prior to lysis in buffer A for 10 minutes 
on ice. Subsequently, cell membranes and nuclei were pelleted by centrifugation at 7000rpm for 10 
minutes. Supernatants (cytosolic extracts) were mixed with 5xLämmli buffer and heated 5 minutes to 
95°C prior to loading on sodium dodecyl sulfate-polyacrylamide-gels. Remaining pellets were washed with 
PBS and buffer A followed by extraction of nuclear proteins with buffer C 30 minutes on ice. After 
centrifugation at 14000rpm for 15 minutes the supernatants (nuclear extracts) were supplemented with 
5xLämmli buffer and treated as described for cytoplasmic extracts. 
 
 
Buffer A       Buffer C 
10mM Hepes, pH 7.9      20mM Hepes, pH 7.9 
1.5mM MgCl2       0.42M NaCl 
10mM KCl       1.5mM MgCl2 
1mM DTT       0.2mM EDTA 
Complete Protease Inhibitor Tablet (Roche)   1mM DTT 
1mM Na3VO4       25% glycerol 
        1mM Na3VO4 
 
 
5.4.3. Alkaline phosphatase treatment of Cell Lysates 
 
For in vitro dephosphorylation of TTP cells were grown on 12-well plates and transfected with a total 
amount of 2µg DNA/well. 24 hours post transfection cells were harvested in PBS and lysed in 50µl 
1xPassive Lysis Buffer (Promega) for 30 minutes on ice. Lysates were divided and one half was treated 
with 20U calf intestine alkaline phosphatase (Roche) for 15 minutes at 37°C. Subsequently, 5xLämmli 
loading dye was added to all lysates before heating to 95°C and loading on 5-12.5% sodium dodecyl 
sulfate-polyacrylamide-gradient gels. 
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5.5. Western Analysis and Densitometry 
 
Purified proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and 
transferred onto nitrocellulose (Hybond-C, Amersham) or PVDF (Millipore) membranes by semidry blotting 
(Peqlab Semidry Blotter) (for conditions see Table II). After blotting, membranes were stained with 
PonceauS solution (Serva) to evaluate loading and subsequently blocked in 5% non fat dry milk in 
PBS/0.1% Tween-20 (Amersham) for 1h at room temperature before incubation with the first antibody (in 
blocking solution; see Table III) over night at 4°C. Secondary antibodies (HRPO-labeled, Amersham; see 
Table IV) were incubated in 1% non fat dry milk in PBS/0.1% Tween-20 for 1 hour at room temperature 
after washing (3x 5 minutes at room temperature) in PBS/0.1% Tween-20. For phospho-specific 
antibodies blocking- as well as incubation-solutions contained tris-buffered saline (TBS) instead of PBS. 
Visualization of Immunocomplexes was carried out by chemiluminescence (Super Signal West Pico, Pierce 
or ECL Detection Reagents, Amersham) on SuperRX films (Fujifilm).  
 
 
Table II: SDS-PA gel conditions 
Resolution gel 5% 7.5% 10% 12.5% 15% 7.5% gradient to 15%* 
Aqua des. 5.75ml 4,95ml 4.1ml 3.3ml 2.45ml 2.5ml       1.25ml 
Solution A 2.5ml 2.5ml 2.5ml 2.5ml 2.5ml       1.25ml       1.25ml 
Solution B 1.7ml 2.5ml 3.4ml 4.2ml 5.0ml       1.25ml         2.5ml 
APS 10% 50µl 50µl 50µl 50µl 50µl          25µl           25µl 
TEMED 10µl 10µl 10µl 10µl 10µl            5µl             5µl 
* gradient gels were prepared using a gradient gel mixer 
Stacking Gel  4% 
Aqua dest. 3.1ml 
Solution Ast 1.25ml 
Solution B 0.65ml 
APS 10% 50µl 
TEMED 10µl 
 
 
 
Solution A         Solution Ast            Solution B 
1.5M Tris-HCl         0.5M Tris-HCl            Acrylamide/Bis-Acrylamide  
0.4% SDS            0.4% SDS             (37.5 :1; Serva) 
pH 8.8              pH 6.8 
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APS 
10% (w/v) Ammoniumperoxydisulphate (Sigma) in aqua dest. 
 
TEMED 
N, N, N’, N’ – Tetramethylen-ethylendiamine (Fluka) 
 
10xRunning buffer      1xTowbin Blotting Buffer 
250mM Tris-Base      25mM Tris-Base 
2M Glycine       192mM Glycine 
1% SDS       1% SDS    
        pH 8.3    
 
 
5.5.1. Primary (Table III) and Secondary (Table IV) Antibodies  
 
 
Table III: Primary Antibodies used for Western Analysis 
Specificity Provider Cat. Number source dilution 
TTP Pavel Kovarik [134] rabbit 1:2000 
TTP N term Santa Cruz sc-8458 goat 1:1000  
IκBα (C-15) Santa Cruz sc-203 rabbit 1:1000  
p65 (A) Santa Cruz sc-109 rabbit 1:1000  
SP1 (PEP2) Santa Cruz sc-59 rabbit 1:500  
β-Actin (I-19) Santa Cruz sc-1616 goat 1:1000  
HA-Tag (probe Y-11) Santa Cruz sc-805 rabbit 1:1000  
Flag-Tag (M1) Sigma F3165-1M6 mouse 1:2000  
Myc-Tag (9E10) Santa Cruz sc-40 mouse 1:1000  
His-Tag (Pentamer) Qiagen #34660 mouse 1:2000 
Phospho- IκBα (Ser32) Cell Signaling #9241 rabbit 1:1000  
Phospho-p38 (Thr180/Tyr182) Cell Signaling #9211 rabbit 1:1000  
Phospho-JNK (Thr183/Tyr185) Cell Signaling #9251 rabbit 1:1000  
JNK  Cell Signaling #9252 rabbit 1:1000  
MEKK1 (43-Y) Santa Cruz sc-437 rabbit 1:500  
p42/44 MAPK (ERK) Cell Signaling #9102 rabbit 1:1000  
Phospho-ERK1/2 (Thr 202/ Tyr 204) Cell Signaling #9106 mouse 1:1000  
GAPDH  Chemicon MAB 374 mouse 1:500 000 
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Table IV: Secondary Antibodies used for Western Analysis 
Specificity Provider Cat. Number source dilution 
α-goat IgG-HRP Santa cruz sc-2020 donkey 1:5000 
α-rabbit IgG-HRP GE Healthcare NA934V donkey 1:5000 
α-mouse IgG-HRP GE Healthcare NA931V sheep 1:5000 
 
 
5.5.2. Densitometry 
 
Densitometric analysis of nuclear p65 levels was done using the background-corrected integrated 
densities of the p65 bands normalized to the SP-1 bands assessed by the ImageJ software freely available 
at http://rsb.info.nih.gov/ij/.  
 
 
5.6. Immunocytochemistry 
 
Cells were seeded onto fibronectin-coated Lab Tek II Chamber Slides (Nunc), transfected with either 
empty vector or mycTTP and 24 hours later stimulated with TNFα (20ng/ml) for the indicated times. Cells 
were fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100 (Sigma). 
Immunostaining of p65 was done using the rabbit-α-p65 antibody (sc-109; Santa Cruz Technology; 
1:500), mycTTP was detected with mouse-α-myc antibody (sc-40, Santa Cruz) followed by goat-α-rabbit 
Alexa 488 (molecular probes) and APC goat-α-mouse (BD Biosciences) secondary reagents at dilutions of 
1:5000 and 1:500, respectively. For translocation of NFAT, cells were transfected with GFP-NFATc and 
mycTTP as described above and stimulated with Ionomycin (500mM final conc.; Sigma). 
 
 
 
5.7. In vivo ubiquitination Assay 
 
To detect ubiquitinated proteins in mammalian cells, HEK 293 cells were grown in 6-well plates to a 
confluency of ~80%. They were transfected using the calcium-phosphate method with 1µg His-tagged 
Ubiquitin (wild type, K48R or K63R mutants) together with 1µg Flag-tagged TTP or 1.5µg of the Flag-
tagged constructs TTPZnC and TTPZnN , and pFcMEKK (plasmid containing the MEKK1 kinase domain; 
Stratagene, PathDetect – trans reporting systems) and HA-tagged TRAF2 and filled up with empty vector 
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to 4µg of total DNA. 24-36 hours post transfection cells were harvested and ubiquitinated proteins were 
detected according to the Tansey lab protocol available at http://tanseylab.cshl.edu/protocols.html. 
Briefly, cells were harvested in PBS and 10% of the cell suspension was separated and mixed with 
5xLämmli loading dye to serve as Input control. The remaining cells were resuspended in 1ml of 
denaturating buffer A, mixed carefully and subjected to sonication for 15 seconds at maximal intensity. 
After centrifugation, the supernatant was incubated with 50µl of Ni-NTA agarose (equilibrated in buffer A; 
Qiagen) for 3 hours at room temperature while constantly rotating. Subsequently, beads were washed 
two times with buffer A, two times with buffer A/TI and once with buffer TI. Finally, the supernatant was 
removed carefully and beads were resuspended in 40µl 2xLämmli loading buffer containing 0.5M 
Imidazol, heated for 10 minutes at 95°C and 30µl were loaded on SDS-Polyacrylamide gels. 
 
 
Buffer A            Buffer TI        Buffer A/TI 
6M Guanidine Hydrochloride        25mM Tris-HCl       1 vol. Buffer A 
0.1M Na2HPO4/NaH2PO4         20mM Imidazole       3 vol. buffer TI 
10mM Imidazole         pH 6.8         
pH 8.0 
 
 
5.8. Co-Immunoprecipitation 
 
For the elucidation of protein-protein interactions, HEK 293 cells were grown in 6-well plates and 
transfected with expression plasmids containing the tagged genes of interest at a confluency of ~80%. 
24-48 hours post transfection, cells were resuspended in 1xLysis Buffer containing 300mM NaCl, 20mM 
Tris-HCl pH 8.0, 1mM EDTA, 0.5% Triton X-100, 0.3% NP-40 as well as protease inhibitors (Complete 
Cocktail, Roche) for 30 minutes on ice. 5-10% of the cell lysates were mixed with 5xLämmli buffer and 
served as Input control later on. Remaining lysates were centrifuged for 15 minutes at full speed at 4°C, 
followed by the over night incubation of the supernatants with the respective antibodies prebound (4 
hours at 4°C) to Protein A/G sepharose (Santa Cruz) according to the manufacter’s instructions. 
Subsequently, sepharose beads were washed three times with lysis buffer, the supernatant was removed 
carefully, remaining beads were resuspended in 2xLämmli buffer and finally subjected to electrophoresis 
on SDS-polyacrylamide-gels. 
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5.9. Gene expression Analysis 
 
 
5.9.1. Preparation of total RNA 
 
Total RNA was purified from cells using the High Pure RNA Isolation Kit (Roche) according to the 
manufacturer’s protocol. Briefly, cells were harvested in PBS and mixed with Lysis/-Binding buffer. 
Subsequently, the cell lysates were applied to High Pure Filter tubes followed by a centrifugation step at 
8000rpm and a direct “on-column” DNAse digestion. The filter tube was washed once with wash buffer I 
and two times with wash buffer II followed by the elution of total RNA with nuclease-free, sterile, double 
distilled water. 
 
 
5.9.2. cDNA Synthesis 
 
Total RNA was subjected to reverse transcription using the GeneAmp RNA PCR kit (Applied Biosystems). 
Routinely, 1µg of RNA was reverse transcribed in a total volume of 20µl using MuLV reverse transcriptase 
and random hexamers as primers. 
 
 
5.9.3. Real-time PCR analysis 
 
For quantitation of gene expression, total RNA was isolated from either HEK 293 cells or MEFs grown in 6-
well plates as described under 5.9.1. 1µg RNA was reverse transcribed and real time PCR was performed 
using 2.5µl of 1:10 diluted cDNA (corresponding to 12,5ng) as template. The PCR was performed using 
the Roche LightCycler utilizing the SYBR green detection method. Experiments were done in triplicates, 
the relative amount of mRNA was calculated using the Pfaffl method and normalization to β2-
microglobulin. Error bars represent standard deviation of the mean. Primer sequences are given in Table 
V.  
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Table V: Real-time PCR primer-sequences 
qPCR primer Sequence 5’-3’ 
human p65 fwd CTA CGA CCT GAA TGC TGT GC 
human p65 rev GCC AGA GTT TCG GTT CAC TC 
mouse p65 fwd GAG CCC ATG GAG TTC CAG TA 
mouse p65 rev CAA AGT TGA TGG TGC TGA GG 
human b2mg fwd GAT GAG TAT GCC TGC CGT GTG 
human b2mg rev CAA TCC AAA TGC GGC ATC T 
mouse b2mg fwd ATT CAC CCC CAC TGA GAC TG 
mouse b2mg rev TGC TAT TTC TTT CTG CGT GC 
human TTP fwd GGA TCT GAC TGC CAT CTA CGA 
human TTP rev CGG GAG GTG ACC CCA GAC 
human TNFα fwd CCC CAG GGA CCT CTC TCT AA 
human TNFα rev GCT TGA GGG TTT GCT ACA ACA 
mouse MCP-1 fwd AGG TCC CTG TCA TGC TTC TG 
mouse MCP-1 rev TCT GGA CCC ATT CCT TCT TG 
mouse Fth1 fwd CCT GCA GGA TAT AAA GAA ACC A 
mouse Fth1 rev GAA GTC ACA TAA GTG GGG ATC A 
mouse Txn2 fwd TGG ACT TTC ATG CAC AGT GG 
mouse Txn2 rev GGC ACA GCT GAC ACC TCA TA 
mouse RANTES fwd GTG CCC ACG TCA AGG AGT AT 
mouse RANTES rev GGG AAG CGT ATA CAG GGT CA 
mouse Gadd45β fwd CCT GGC CAT AGA CGA AGA AG 
mouse Gadd45β rev TGA CAG TTC GTG ACC AGG AG 
mouse TRAF1 fwd CCT GAG AGA TGA TGA GGA TCG 
mouse TRAF1 rev GCT CCC CTT GAA GGA ACA G 
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6. ABBREVIATIONS 
 
 
 
AdV  adenovirus 
AMD  ARE-mediated-decay 
AP-1  activator protein 1 
ARE  AU-rich elements 
BAFF  B cell activating factor 
CBP  CREB-binding-protein 
CCCH  cystein-cystein-cystein-histidin 
C/EBP  CCAAT enhancer binding protein 
CIAP  calf intestine alkaline phosphatase 
Cox-2  cycloocygenase 2 
CREB  cyclic adenosine monophosphate responsive element binding protein 
ERK  extracellular signal-regulated kinase 
FACS  fluorescence activated cell sorting 
FADD  fas-associated death domain 
GM-CSF  granulocyte macrophage colony stimulating factor 
GPCR  G-protein-coupled receptor 
GSK-3  glycogen synthase kinase-3  
HDAC  histon deacetylase 
HEK  human embryonic kidney 
HUVEC  human umbilical vein endothelial cells 
IAP  inhibitor of apoptosis 
ICAM  intercellular adhesion molecule 
IEG  immediate early gene 
IER3  immediate early response 3 
IFN  Interferon 
IκB  inhibitor of κB proteins 
IKK1  inhibitor of kappa B kinase 1  
IKK-K  inhibitor of kappa B kinase kinase 
IL  Interleukin 
iNos  inducible nitric oxide synthase 
JNK  c-Jun N-terminal kinase 
K.o  knock out 
LPS  Lipopolysaccharide 
MAPK  mitogen activated protein kinase 
MEF  mouse embryonic fibroblast 
MEKK1  mitogen-activated protein kinase extracellular signal-regulated kinase kinase    
 kinase-1 
MHC  major histocompatibility complex 
NES  nuclear export signal 
NF-κB  nuclar factor-kappaB 
NIK  NF-κB - inducing kinase 
NLS  nuclear localization signal 
NPC  nuclear pore complex 
PHD  plant homeodomain 
PI3K  phosphoinositide-3-kinase 
PKA  protein kinase A 
PKCα  protein kinase C alpha  
PKCβ  protein kinase C beta  
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PKCγ  protein kinase C gamma   
PKCζ  protein kinase C zeta  
PP2A  protein phosphatase 2A 
RHD  Rel-homology domain 
RIP  receptor-interacting protein 
SMRT  silencing mediator of retinoic acid and thyroid hormone receptor 
TAB1/2  TAK-binding proteins 1/2 
TAD  transcriptional activation domain 
TAK1  TGFβ activated kinase 1 
TGFβ  transforming growth factor β 
Tis  TPA inducible sequence 11 
TNFα  tumor necrosis factor 
TNFR  TNF-receptor 
TPA  12-O-tetradecanoylphorbol-13-acetate 
TRADD  TNF receptor-associated death domain 
TRAF  TNF-receptor-associated factor 
TTP  Tristetraprolin 
TZF  tandem zinc finger 
UIM  ubiquitin interacting motifs 
UTR  untranslated region 
VCAM  vascular cell adhesion molecule 
wt  wild type 
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